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Nutritional research is currently entering the ﬁeld of personalized nutrition, to
a large extent driven by major technological breakthroughs in analytical
sciences and biocomputing. An eﬃcient launching of the personalized
approach depends on the ability of researchers to comprehensively monitor
and characterize interindividual variability in the activity of the human
gastrointestinal tract. This information is currently not available in such a
form. This review therefore aims at identifying and discussing published data,
providing evidence on interindividual variability in the processing of the major
nutrients, i.e., protein, fat, carbohydrates, vitamins, and minerals, along the
gastrointestinal tract, including oral processing, intestinal digestion, and
absorption. Although interindividual variability is not a primary endpoint of
most studies identiﬁed, a signiﬁcant number of publications provides a wealth
of information on this topic for each category of nutrients. This knowledge
remains fragmented, however, and understanding the clinical relevance of
most of the interindividual responses to food ingestion described in this
review remains unclear. In that regard, this review has identiﬁed a gap and
sets the base for future research addressing the issue of the interindividual
variability in the response of the human organism to the ingestion of foods.
Dr. B. Walther, D. Gille, A. Schmid, Dr. G. Vergères
Agroscope
Federal Department of Economic Aﬀairs
Education and Research EAER
3003 Berne, Switzerland
E-mail: guy.vergeres@agroscope.admin.ch
Dr. A. M. Lett
Section for Nutrition Research
Department of Medicine
Imperial College London
London, UK
The ORCID identiﬁcation number(s) for the author(s) of this article
can be found under https://doi.org/10.1002/mnfr.201900677
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original
work is properly cited, the use is non-commercial and no modiﬁcations
or adaptations are made.
DOI: 10.1002/mnfr.201900677
1. Introduction
The “food domain” and the “human do-
main” are tightly connected, and their
reciprocal interactions are modulated by
diﬀerent factors, inter alia, ethnicity, cul-
ture (including gastronomy), economy,
or politics. All such factors are drivers
of diﬀerent food choices and dietary pat-
terns, and in turnmodulate human phys-
iology and health, via nutrient intake and
absorption. A famous aphorism, which
represents the connection between the
food and human domains, was ﬁrst used
in a 1825 gastronomy book by Jean An-
thelme Brillat-Savarin, “Dis-moi ce que
tu manges, je te dirai ce que tu es.” [Tell
me what you eat, and I will tell you what
you are].[1]
Processing has long been used to
ameliorate sensory, safety, and nutri-
tional characteristics of food. The impact
of processing is still an important re-
search topic for both academia and the
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food industry. In regards to health, it is recognized that even mi-
nor changes in processing can lead to signiﬁcant changes in the
foods eﬀect. However, the impact of changes in the most signiﬁ-
cant processing procedure applied by man on food, digestion in
the gastrointestinal tract (GIT), is seldom considered.
As with any other human characteristic, physical or mental,
events in the GIT are subject to variability between individuals.
This variability can aﬀect the ﬁnal output, for example, leading to
diﬀerent digestion or absorption capacity of speciﬁc components,
in turn leading to a diﬀerent eﬀect on physiology and health. In
few words, “Tell me what you digest and absorb, and I will tell
you what you are” would be more correct than Brillat–Savarin’s
aphorism. However to date, knowledge on human variability in
the GIT is limited and fragmented, and has not been compiled
in a comprehensive form encompassing all nutrients.
This review (GutSelf) provides an overview of the knowledge
and published data on human interindividual variability in the
processing of nutrients by the GIT. This task requests a multi-
factorial analysis speciﬁcally considering the class of nutrients
(protein, fat, carbohydrates, vitamins, and minerals) as well as
the functionality of the GIT (oral processing, intestinal digestion,
and absorption). In addition, a range of interrelated variables
modulating the processing of food by the GIT needs to be
considered. In particular, published evidence for interindividual
variability was identiﬁed for the following variables: chewing,
nutrient sensing, saliva composition, nutrient digestibility, com-
position of the intestinal peptidome, enzymatic activity, genetic
polymorphisms, body mass index (BMI), diet, circadian rhythm,
and the gut microbiota. These variables can be categorized as
intrinsic (e.g., genetic polymorphisms) or extrinsic (e.g., diet),[2,3]
molecular (e.g., pepsin activity), or morphological (e.g., BMI),
and of genetic (e.g., amylase polymorphism) or non-genetic
origin (although a non-genetic origin is often diﬃcult to demon-
strate). In light of this complexity, this review is organized in
three hierarchical levels: the ﬁrst level corresponds to the classes
of nutrient; the second level corresponds to the GIT functions;
the third level corresponds to the variables associated with the
interindividual variability.
Interindividual variability is rarely addressed by researchers as
a primary endpoint. A systematic search of the literature based on
a well-deﬁned selection of keywords was therefore unsuccessful,
delivering either thousands of unspeciﬁc hits with a broad search
strategy, or very few hits with narrow search strategies. Being the
ﬁrst of its kind, this review does not intend to be complete but, in-
stead, to present the main evidence for such variability. Of note,
the post-absorptive fate of the nutrients, e.g., liver metabolism,
is not part of this review. We also exclude the impact of ag-
ing on GIT processing as this topic has already been reviewed
elsewhere.[4] Finally, the European Cooperation in Science and
Technology (COST) Action FA1403 (POSITIVe) has reviewed in-
terindividual variation in response to consumption of plant food
bioactives (https://www6.inra.fr/cost-positive) and the reader is
referred to ongoing work and publications by the COST action
on this topic.[5,6] Of note, although the concept of nutrikinetics
covers absorption, distribution, metabolism, and excretion, our
review focuses on the ﬁrst part of this process (absorption) me-
diated by the GIT.
2. Proteins
2.1. Overview of Protein Processing by the GIT
The assimilation of proteins involves gastric and pancre-
atic enzymatic hydrolysis to luminal oligopeptides and free
amino acids.[7] The low pH in the stomach activates pepsino-
gen to pepsin. Pepsin cleaves peptide bonds at the aro-
matic amino acids, and results in a mixture of intermedi-
ate protein moieties and peptides. These are then delivered
to the duodenum, where pancreatic proenzymes (trypsinogen,
chymotrypsinogen, proelastase, and procarboxypeptidase) be-
come activated by mucosal enterokinase and further break-
down these products into amino acids, dipeptides, and tripep-
tides. Part of the latter are hydrolyzed to amino acids
by brush border dipeptidases.[8] Then the remaining dipep-
tides and tripeptides, together with the amino acids, are ab-
sorbed by the enterocytes of the small intestine, via a spe-
ciﬁc group of amino acid transporters, and speciﬁc mem-
brane proteins, such as peptide transporter 1 (PEPT1), for
peptides.[7]
Amino acid transport activities in the enterocyte are frequently
referred to as “systems”; the term indicates a functionally iden-
tiﬁed transport activity that appears to be similar in a variety of
cell types. Amino acid transport systems have been described on
both apical and basolateralmembranes. They vary in solute speci-
ﬁcity, being dependent of Na+, Cl−, H+, or K+. The basolateral
system carriers may work in either direction and may represent
an electroneutral or electrogenic transport process, depending on
the luminal amino acid concentration and cellular demand and
on the electrogenic driving forces.[8] The encoded gene of amino
acid transporters has been identiﬁed and belongs to the solute
carrier (SLC) superfamily.[9]
Dipeptides and tripeptides are very eﬃciently absorbed in the
small intestine. The process is indirectly Na+-dependent, in that
Na+ is necessary for the activity of Na+/H+ exchanger (NHE) 3
to generate a proton gradient for H+/peptide co-transport. Thus,
the two transport processes are functionally coupled. Peptides
of four or more amino acids in length are poorly absorbed
in a non-carrier dependent mechanism. The carrier responsi-
ble for the intestinal uptake of peptides is known as peptide
transporter 1 (PEPT1). It is encoded for by the SLC15A1 gene,
and is expressed in the intestinal, and to a lesser extent, renal
epithelia.
Inside enterocytes, most peptides are hydrolyzed, and the re-
sulting amino acids are released together with those absorbed
by amino acid transporters. Through the blood, amino acids are
delivered to all tissues, where they serve as building blocks for
protein synthesis, as precursors for a wide variety of bioactive
molecules, and as energy metabolites.[10]
Among the variables presented in the last paragraph of the In-
troduction, a search of the literature has identiﬁed convincing
evidence for the interindividual of the oral processing, digestion,
and intestinal absorption of proteins by the GIT for the follow-
ing variables: chewing, protein digestibility, composition of the
intestinal peptidome, pepsin and chymotrypsin activity, and ge-
netic polymorphisms.
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2.2. Interindividual Variability in Oral Processing of Proteins
2.2.1. Chewing
In previous years, a large amount of evidence has shown that the
kinetics of macronutrient breakdown during digestion, and thus,
the bioavailability of nutrients, are strongly modulated by the
structure the food adopts in the diﬀerent compartments of the
GIT.[11] For solid and semi-solid foods, the ﬁrst step of disintegra-
tion occurs in the mouth, where the chewing process and saliva-
soaking result in the formation of a bolus that will be further swal-
lowed. Signiﬁcant interindividual variation in oral processing is
observedwithin humans,[12] with some people chewing their food
intensively leading to the formation of small particles, and others
only partly, resulting in large particles. This has been particularly
described in elderly populations, where dental health problems
may lead to a bolusmade of large particles. For instance, Rémond
et al.[13] studied the digestion of beef meat in elderly with intact or
impaired dentition. Twenty elderly volunteers aged 60–75 years
were involved in the study. Ten volunteers had healthy natural
dentition, with the remaining ten being edentulous and wore
complete dentures. A rapid increase in plasma aminoacidemia
and plasma leucine entry rate was observed after meat intake in
healthy subjects. In complete denture wearers, the increase in
leucine entry rate was delayed, and the amount of leucine appear-
ing in peripheral blood during the whole postprandial period
was lower than that in healthy subjects. Postprandial whole-body
protein synthesis was lower in denture wearers than in healthy
subjects (30% compared with 48% of leucine intake, respec-
tively). As such, this study showed that meat protein utilization
for protein synthesis can be impaired by a decrease in chewing
eﬃciency.
Following this study, Pennings et al. observed similar trends by
following another strategy, comparing the digestion and amino
acid bioavailability of minced beef versus beef steak.[14] Ten older
men (mean ± SEM age 74 ± 2 years) were randomly assigned to
a crossover experiment that involved two treatments, in which
they consumed 135 g of l-[1-13C]phenylalanine–labeled beef,
which was provided as beef steak or minced beef. Meat con-
sumption was combined with continuous intravenous l-[ring-
2H5] phenylalanine and l-[ring-2H2] tyrosine infusion to assess
beef protein digestion and absorption kinetics as well as whole-
body protein balance and skeletal muscle protein synthesis rates.
Meat protein–derived phenylalanine appeared more rapidly in
peripheral circulation afterminced beef than after beef steak con-
sumption. Also, its availability in the circulation during the 6
h postprandial period was greater after minced beef than after
beef steak consumption (61 ± 3% compared with 49 ± 3%, re-
spectively). Whole-body protein balance was more positive after
minced beef than after beef steak consumption (29± 2 compared
with 19 ± 3 mmol phenylalanine kg–1, respectively). However,
skeletal muscle protein synthesis rates did not diﬀer between
treatments when assessed over a 6 h postprandial period. In con-
clusion, minced beef was more rapidly digested and absorbed
than beef steak, which resulted in increased amino acid availabil-
ity and greater postprandial protein retention.
These two original studies clearly demonstrate that variability
in chewing eﬃciency, and thus post-oral processing food struc-
ture, can directly aﬀect the kinetics of protein hydrolysis and the
bioavailability of amino acids. Although to our knowledge, there
are no other similar studies within a more general adult popu-
lation, one can hypothesize that diﬀerences in chewing behavior
between adults, even with healthy dentition, may regulate amino
acid bioavailability.
2.3. Interindividual Variability in Digestion of Proteins
2.3.1. Protein Digestibility
Protein quality evaluation aims to assess the contribution of di-
etary protein in satisfying the metabolic needs for nitrogen and
essential amino acids.[15] To this aim, the Food and Agriculture
Organization (FAO) has proposed indexes for evaluating protein
quality.[15–17] Protein digestibility mirrors the extent of protein di-
gestion and intestinal absorption and thus the amount of amino
acids made available for metabolism. Protein digestibility has
been shown to ﬂuctuate signiﬁcantly according to the diet, es-
pecially between those of developed and developing countries,
where in developing countries the diet is richer in anti-nutritional
factors and in ﬁbers that can limit protein digestibility.[18]
Table 1 summarizes the true ileal and fecal digestibility and
the variability of the values obtained. The coeﬃcients of variation
(CV) shown in the table provide an estimation of the interindi-
vidual variability assuming that the analytical variability is lower.
Interestingly, the two proteins with the lowest ileal digestibility
(<85%), likely due to their compacted structure[19,20] and the
presence of trypsin inhibitor in raw egg,[19] present the highest
CV, with 42.7% CV for a raw egg digestibility of 51.3%[19] and
10.5% CV for a rapeseed isolate digestibility of 84.0%,[20] thus
indicating a high interindividual variability. This could be the
result of a diﬀerent response from the proteases toward anti-
nutritional factors and/or toward resistant protein, which could
be a result of the probable dependence on the levels of enzyme
secretion and/or activity among individuals. It should be noted
that the high CV for rapeseed digestibility was due to a sole sub-
ject, who showed no reason to be excluded,[20] but without whom
the CV was decreased by 3 (CV of 3.6%) for a digestibility of
87.1%. For the other protein sources, all other CV are below 8%
suggesting low interindividual variability. This is probably due
to the fact that these CV relate to more easily digestible dietary
proteins (>85%), and that the variation between individuals is
low in relation to this high digestibility. It could be interesting to
estimate the interindividual variability in other proteins showing
lower values of digestibility, such as plant proteins within their
vegetal matrix containing anti-nutritional factors. Endogenous
losses should also be estimated for each subject as this may
vary across individuals. The true fecal digestibility presented
in Table 1 has been estimated after correction for a constant
value of obligatory endogenous losses, which likely alters real
variability.
2.3.2. Composition of the Intestinal Peptidome
Boutrou and colleagues[21] equipped human volunteers with a
double-lumen nasogastric tube that migrated to the proximal
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Table 1. True ileal and fecal digestibility in humans. Interindividual variability is represented by the coeﬃcient of variation (CV).
Protein source Reference True digestibility (%)
n Mean SD CV
Ileal digestibility
Animal protein
Skimmed milk pasteurised [231] 5 95.5 0.9 0.9
Protein milk alone [232] 7 94.8 1.6 1.7
Protein milk with fat [232] 9 94.5 3.0 3.2
Protein milk with sucrose [232] 9 94.6 1.5 1.6
Intact casein [233] 6 94.1 1.5 1.5
Hydrolysed casein [233] 5 92.3 1.3 1.4
Bovine meat, cooked at 55 °C, 5 min [234] 8 94.1 2.0 2.1
Bovine meat, cooked at 90 °C, 30 min [234] 8 90.1 5.9 6.6
Egg protein, raw [19] 5 51.3 21.9 42.7
Egg protein, cooked [19] 5 90.9 1.8 2.0
Plant protein 0.0
Wheat toast (15N gluten) [235] 9 90.3 4.3 4.8
Soy protein isolate [236] 11 91.8 1.9 2.1
Soy protein isolate with sucrose [236] 10 90.9 2.2 2.4
Pea ﬂour (Pisum Sativum, Solara cultivar) [237] 7 89.4 1.1 1.2
Pea globulins (Pisum Sativum, Baccara cultivar) [238] 9 94.0 2.5 2.7
Pea globulins + albumins (Pisum Sativum, Baccara cultivar) [238] 8 89.9 4.0 4.4
Lupin ﬂour (Lupinus Albus, cultivar Arès) [239] 7 91.0 3.0 3.3
Rapeseed isolate (Brassica Napus L., Goeland cultivar) [20] 7 84.0 8.8 10.5
Fecal digestibility
Animal protein
Egg [240] – 97.0 3.0 3.1
Egg, spray-dried [241] 5 92.2 1.6 1.7
Milk, cottage cheese [241] 4 99.1 1.8 1.8
Milk, cheese [240] – 95.0 3.0 3.2
Tuna, canned [241] 4 89.9 1.0 1.1
Meat, ﬁsh [240] – 94.0 6.0 6.4
Plant protein
Maize [240] – 85.0 4.0 4.7
Rice, polished [240] – 88.0 5.0 5.7
Wheat, whole [240] – 86.0 4.0 4.7
Wheat, reﬁned [240] – 96.0 7.0 7.3
Wheat gluten [241] 4 93.8 3.0 3.2
Oatmeal [240] – 86.0 7.0 8.1
Soy ﬂour [240] – 86.0 7.0 8.1
Soy isolate [241] 4 94.8 4.4 4.6
Peanut ﬂour [241] 4 90.8 2.0 2.2
Mixed protein source
Low ﬁber control diet [242] 7 95.1 1.5 1.6
High ﬁber diet (coarse whole meal rye bread) [242] 7 90.7 1.4 1.5
High ﬁber diet (ﬁne whole meal rye bread) [242] 7 90.8 2.2 2.4
All ileal studies used 15N-labelled protein sources ingested by healthy adults equipped by a naso-ileal tube, except when noted. Ileal digesta were collected in ileostomy
patients. True fecal digestibility was estimated by correcting apparent digestibility with a constant value of obligatory endogenous losses (9–12 mg N kg–1 body weight d–1).
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jejunum to characterize the composition of the postprandial
intestinal peptidome. Sample collection was performed for 6 h
after the ingestion of 30 g 15N-labeled casein or whey proteins.
Nitrogen ﬂow rates were measured, and peptides were identi-
ﬁed by using mass spectrometry (MS). After casein ingestion,
medium-size peptides (750–1050 kDa) were released during 6
h, whereas larger peptides (1050–1800 kDa) were released from
whey proteins in the ﬁrst 3 h. Peptides originating from caseins
that coagulate in the stomach and are released slowly in the small
intestine, were observed all over the 6 h postprandial period,
whereas the number of those released from whey proteins,
which are “fast proteins” that remain soluble in the stomach
and are rapidly transferred, digested, and absorbed in the small
intestine, strongly peaked after 1 h and were nondetectable after
5 h. 𝛽-Casein was the most important precursor of peptides, in-
cluding bioactive peptides with various activities. The amounts of
𝛽-casomorphins (𝛽-casein 57–, 58–, 59–, and 60–66) and 𝛽-casein
108–113 released in the postprandial window were found in the
lumen in concentrations suﬃcient to elicit the biological action
of these peptides (i.e., opioid and antihypertensive, respectively).
Of note, the amounts of peptides derived from casein and whey
protein digestion were characterized by high standard deviations
(SDs) (i.e., mostly signiﬁcantly above 50%) across all peptide
sizes and digestion times, which suggests a large variability in
protein digestion among the subjects. These results indicate that
omics analytical strategies (including peptidomics) potentially
allow a holistic visualization of interindividual variability in food
processing by the GIT, which takes into account a wide range
of molecules (or groups of molecules) with potentially diﬀerent
degrees of interindividual variability.
2.3.3. Protease Activity
When comparing pepsin activity in subjects with ulcers ver-
sus healthy subjects, Le Veen and Hallinger[22] observed dra-
matic interindividual variability. In healthy subjects, pepsin ac-
tivity ranged from 188 to 8600 U mL–1 of gastric juice, whereas
for patients suﬀering from ulcers, activities ranging from 940 U
to 11 200 U mL–1. Similarly, Janowitz and Hollander[23] found
pepsin output ranging from 0 to 8335 HgbU h–1 in healthy
individuals with a mean value of 4119 HgbU mL–1. Interest-
ingly, these authors reported a positive correlation between the
amounts of pepsin and acid secreted per hour, proposing that
the peptic and parietal cells respond to common inﬂuences of
vagal origin. These conclusions provide an early indication of the
powerful potential of variables demonstrating high interindivid-
ual variability in human studies to propose relevant mechanistic
hypothesises.
Of note, pepsin activity was at its lowest before food ingestion
then gradually increased over the day.[23] The changes are partly
attributed to diﬀerences in pH of the gastric aspirates, the low-
est values being observed when the pH was at its highest. There-
fore, among the factors that can explain interindividual variability
among subjects for pepsin activity in the stomach, the evolution
of the pepsin secretion over the day also needs to be taken into
account within each individual.
Using N-benzoyl-l-tyrosine ethyl ester as substrate, Rick[24]
found chymotrypsin activities ranging from 28.4 to 154 U min–1
in adults. Parallel evolution of chymotrypsin and trypsin was
described by Norman et al.[25] in infants, who determined a
trypsin/chymotrypsin ratio ranging from 0.5 to 2.0, varying
slightly during the test meal within-subject, but greatly from one
infant to the other.
2.4. Interindividual Variability in Intestinal Absorption of Amino
Acids and Peptides
2.4.1. Genetic Polymorphisms
The lack of intestinal absorption of amino acids or peptides is
associated with a range of disorders, including cystinuria, Hart-
nup disorder, inﬂammatory bowel diseases (IBDs), obesity, and
abnormal dietary behavior. However, most of these disorders
are multifactorial and a direct link between them and intesti-
nal absorption is diﬃcult to establish. The following paragraphs
present some of these cases.
Cystinuria is an autosomal inherited metabolic disorder char-
acterized by impaired transport of cystine and dibasic amino
acids in the proximal renal tubule and the GIT. Mutations in the
amino acid transporters SLC3A1 and SLC7A9T are responsible
for cystinuria.[26,27]
Mutations in the neutral amino acid transporter B0AT1
(SLC6A19) is known to harbor mutations in Hartnup disorder.
Hartnup disorder, an autosomal recessive defect, named after a
English family with this condition in 1956, and results from im-
paired transport of neutral amino acids across epithelial cells in
renal proximal tubules and intestinalmucosa. Symptoms include
transient manifestations of pellagra (rashes), cerebellar ataxia,
and psychosis. Using homozygosis mapping in the original
family in whom Hartnup disorder was discovered, the location
of one causative gene on chromosome 5p15 was conﬁrmed. This
region is homologous to the area of mouse chromosome 13 that
encodes the sodium-dependent amino acid transporter B(0)AT1.
The protein product of SLC6A19, the Hartnup transporter, is ex-
pressed primarily in the intestine and renal proximal tubule, and
functions as a neutral amino acid transporter.[28] The lack of in-
testinal tryptophan transport appears to be responsible for most,
if not all, clinical phenotypes of Hartnup disorder. In agreement
with this observation, clinical symptoms are mainly observed
in individuals with lower than normal plasma amino acid
concentrations.[10]
Polymorphisms in the intestinal transporter PEPT1 (encoded
by SLC15A1) are associated with IBDs, such as Crohn’s disease
(CD) and ulcerative colitis (UC), as the polymorphisms aﬀect the
gut epithelial barrier and interactions with bacteria. PEPT1 me-
diates intracellular uptake of bacterial products that can induce
inﬂammation and NF-𝜅B activation upon binding to NOD2, a
protein sensing bacterial peptidoglycan and stimulating host im-
mune response, which is often mutated in CD. Twelve SLC15A1
single nucleotide polymorphisms (SNPs) were genotyped in a
study conducted in 1783 individuals from two cohorts of Swedish
and Finnish IBD patients and controls. The common allele (C) of
a coding polymorphism (rs2297322, Ser117Asn) was associated
with CD susceptibility in both cohorts, but with genetic eﬀects in
opposite directions (risk and protection, respectively). The best
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evidence of association was found in both populations when the
analysis was performed on individuals not carrying NOD2 com-
mon risk alleles (Swedish cohort: OR 1.97, 95% conﬁdence inter-
val [CI] 1.34–2.92; Finnish cohort: OR 0.63, 95% CI 0.44–0.90).
Compared to PEPT1-Asn117 the PEPT1 variant encoded by the
C allele (PEPT1-Ser117) was associated with reduced signaling
downstream of NOD2. Therefore, a functional polymorphism
in SLC15A1 might modulate the inﬂammatory and antibac-
terial response in IBDs. However, further studies are needed
to identify if the polymorphism truly contributes to disease
susceptibility.[29]
Polymorphisms in neutral and cationic amino acid transporter
ATB0+ (SLC6A14) are associated with obesity. Single nucleotide
polymorphism (SNP) 22 510 C>G (rs2071877), located in the
three untranslated regions of SLC6A14, has been strongly as-
sociated with obesity in the Finnish population. Furthermore, a
haplotype including this SNP, together with SNP 20 649 C>T
(rs2011162, located in intron 12), showed a signiﬁcantly diﬀer-
ent allele frequency in obese versus control subjects. A study by
Durand et al.[30] genotyped SNPs 20 649 C>T and 22 510 C>G in
1267 obese and in 649 unrelated non-obese normo-glycemic sub-
jects, all of French-Caucasian origin. Both SNPs were associated
with obesity ([OR] 1.23, 95% CI 1.04–1.45 and 1.36, 1.16–1.59,
respectively). These results conﬁrmed the observation of Suvio-
lahti et al.[31] in Finnishmen (117 obese and 182 control subjects)
as the most frequent alleles for both SNPs were associated with
increased obesity. Durand et al.[30] analyzedmen and women sep-
arately and concluded that only women appeared to contribute to
the association of obesity with SNP 20 649 C>T. On the other
hand, both sexes contributed to the association with SNP 22 510
C>G.
Interestingly, Durand et al.[30] further explored the potential
contribution of SLC6A14 variants in dietary behavior. This study
was motivated by the fact that SLC6A14 encodes for an amino
acid transporter that may aﬀect tryptophan availability for sero-
tonin synthesis and that serotonin is a neurotransmitter involved
in a wide spectrum of behaviors, including dietary habits. Ap-
plying the Three-Factor Eating Questionnaire (TFEQ)[32] to an
obese cohort to measure hunger and disinhibition scores, SNPs
in SLC6A14 were associated with the dietary behavior of obese
women (BMIs 30–40 kg m–2), but not of morbidly obese women
(BMI > 40 kg m–2). Moderately obese women homozygous for
the at-risk allele 22 510 C>G had also higher hunger and disinhi-
bition scores. A similar result was observed with both scores for
SNP 20 649 C>T. However, no association was observed when
all obese adults were pooled as well as in the subgroup of obese
adult men.
The mechanism by which SLC6A14may participate in obesity
and possibly in the control of dietary behavior is still uncertain
and further studies are required. Nevertheless, genes involved
in the serotonin signaling pathway have been associated with
several obesity-related phenotypes.[30] However, the association
between 22 510 C>G and the disinhibition and hunger scores
of the validated TEFQ questionnaire, although modest and
only observed in moderately obese women, suggests a role of
SLC6A14 on food intake,[27] in particular since disinhibition
determines the loss of control over food intake under a va-
riety of situations and is well correlated to binge eating and
overeating.[33]
3. Fat
3.1. Overview of Fat Processing by the GIT
Triacylglycerols (TAGs) (also named triglycerides) represent the
major class of lipids in food. Two additional classes of lipids,
phospholipids (PLs) (in particular glycerophospholipids-GPLs),
and cholesterol esters (CEs) are also important sources of dietary
lipids. Fat digestion takes place in three phases, namely the oral,
gastric, and intestinal phases,[34,35] starting in the mouth with
mastication.
The free fatty acids (FAs) present in the masticated food bo-
lus activate sensory receptors on the taste buds.[36] Activation of
these receptors leads to the calcium-mediated release of neuro-
transmitters and hormones that signal the presence of dietary fat
to the brain.[37] Oral FA signaling also modulates a range of nu-
tritional factors including fat intake, appetite regulation, absorp-
tion of fat-soluble nutrients such as vitamin A, and the storage of
lipids in the GIT.[38]
Processing of TAGs by the GIT requires that the ingested
fats be hydrolyzed into FAs and monoacylglycerols (MAGs). Be-
cause of their hydrophobicity TAGs need to be emulsiﬁed to be
made available for hydrolysis.[35] Only 10–30% of dietary fat is
hydrolyzed in the stomach, which helps the digestive process
create an emulsion by mechanical action.[34,39,40] Gastric lipase
hydrolyzes TAGs mainly at position sn-3 containing short- and
medium-chain FAs (< C12) that are directly transferred to the
blood.[41]
Fats enter the duodenum and stimulate the secretion of the
peptides cholecystokinin (CCK) and secretin by enteroendocrine
cells, stimulating the contraction of the gallbladder and the re-
lease of bile and pancreatic juice (containing lipase and colipase).
Bile acts as a surfactant producing an emulsion of ﬁne oil droplets
increasing surface area and thus rendering lipids more easily ac-
cessible to the pancreatic enzymes.[34,42–44]
After digestion, the hydrolyzed lipid-soluble components
(long-chain FAs, 2-MAGs, lyso-PLs, free cholesterol (FC)) inte-
grate with bile salts into mixed micelles to diﬀuse between the
intestinal microvilli to interact with the luminal surface of the
enterocytes. The FAs produced by fat digestion actively modu-
late lipid processing by the GIT. The binding of FAs to recep-
tors on enteroendocrine cells promotes the activation of satiety
hormones (leptin, CCK, peptide YY (PYY), glucagon-like pep-
tide 1 (GLP-1)), the inhibition of hunger hormones (ghrelin),
and the intestinal uptake of FAs.[45] The absorption of lipids is
a complex, two-step process including lipid transfer from the in-
testinal lumen into enterocytes and their subsequent secretion
into lymph/portal vein. The transport is mostly an active process
driven by protein transporters, particularly at lower concentra-
tions and may also involve diﬀusion when free FA concentration
in the lumen exceeds that within cells.[46] Protein-mediated FA in-
testinal uptake involves CD36, FA transport protein 4,[47] intesti-
nal FA-binding protein (I-FABP; FABP2), and liver-type FABP
(LFABP; FABP1).[48] The absorption of FAs and MAGs is highly
eﬃcient, with more than 95% of ingested dietary lipid being ab-
sorbed in vivo.[49]
Although the entire length of the small intestine can absorb
cholesterol from the lumen, the major sites of absorption are
the duodenum and proximal jejunum. Niemann–Pick C1-Like
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Figure 1. Overview of molecular variables contributing to inter-individual variability in the processing of fat by the GIT.
1 (NPC1L1) and ATP-binding cassette transporters G5 and G8
(ABCG5/ABCG8) serve as opposing gatekeepers in the liver and
intestine to tightly regulate whole body sterol homeostasis.[50,51]
The eﬃciency of lipids absorption is determined by the net ef-
fect between inﬂux and eﬄux of intraluminal molecules (mainly
FAs and cholesterol) crossing the brush border membrane of
the enterocyte.[52] Cholesterol secretion by enterocytes occurs by
apoB-dependent (chylomicrons (CMs)) and apoB-independent
(HDL) pathways.[53] Most of the absorbed cholesterol molecules
coming from the diet and from the bile, reach the endoplasmic
reticulum, where acyl-CoA:cholesterol acyltransferase 2 (ACAT2)
esteriﬁes them. CEs are then assembled into the core of CM
particles. Once across the intestinal microvillus membrane,
FAs and MAGs are resynthesized to TAGs by acyl-coenzyme
A:monoacylglycerol acyltransferases (MGAT1, 2, and 5) and acyl-
coenzyme A:diacylglycerol acyltransferases (DGAT1 and 2). CMs
assembly and secretion is critically dependent on microsomal
triglyceride transfer protein (MTP) and apoB-48.[54,55] The trans-
membrane 6 super family member 2 protein (TM6SF2) is also
involved in packaging and secretion of dietary lipids in TAG-rich
lipoproteins.
Among the variables presented in the last paragraph of the In-
troduction, a search of the literature has identiﬁed convincing
evidence for interindividuality in oral processing, digestion, and
intestinal absorption of fat by the GIT for the following variables:
FA sensing, genetic polymorphisms, saliva composition, BMI,
diet, and circadian rhythm. These variables are summarized in
a schematic manner in Figure 1.
3.2. Interindividual Variability in Oral Processing of Fat
3.2.1. FA Sensing
The ﬁrst evidence for interindividual variability in fat tasting
was published in 1997 by Tepper and Nurse.[56] Their study
revealed that, in contrast to non-tasters, medium- and super-
tasters of the bitter compound 6-n-propylthiourail (PROP) were
able to discriminate a salad dressing containing 40% fat from
a dressing containing 10% fat. In a randomized, single blind,
placebo-controlled crossover design study, Kamphuis et al.[57]
later identiﬁed linoleic acid tasters and linoleic acid non-tasters
based on their ability to identify the presence of 10 µm linoleic
acid. Mattes[58] measured the oral detection thresholds for a
range of FAs (linoleic acid, stearic acid, lauric acid, caproic
acid) in healthy subjects. These thresholds covered 3–4 orders
of magnitudes ranging from below 0.001% (w/v) to above 1%
(w/v). Galindo et al.[59] measured threshold concentrations for
“fatty” orosensation between 0.1 and 0.4 mm for a range of
FAs (C18:1–C20:4). The “scratchy” orosensation was detected
at higher concentrations up to 2.2 mm and showed signiﬁcantly
higher interindividual variance relative to the “fatty” orosen-
sation. Steward et al.[60] determined the oral FA sensitivity of
healthy subjects, which ranged from 0.02 to 6.4 mm and spanned
two orders of magnitude for each of the FA tested (lauric acid,
stearic acid, oleic acid, linoleic acid). Of note, within the group
of hyposensitive subjects reported, signiﬁcantly higher intake
of total energy, fat, and carbohydrates (but not proteins), and
monounsaturated and polyunsaturated fat was observed.
The results by Steward et al.[60] were conﬁrmed and comple-
mented by a later study integrating dietary habits to the range
of variables associated with oral FA sensing.[61] In this study, the
subjects were ﬁrst characterized in their response to oleic acid
and classiﬁed as hyposensitive and hypersensitive. Compared to
the hypersensitive group, the hyposensitive group scored lower
in the fat ranking test, consumed more energy, total fat (but not
carbohydrates and proteins), saturated fat, and polyunsaturated
fat. The dietary habits also diﬀered, the hyposensitive group of
subjects consuming greater amounts of full-fat dairy, saturated
fat from dairy, meat, eggs, and spreads as well as saturated fat
from spreads. Hyposensitive subjects also consumed less low-fat
cheese. These diﬀerences in intake of foods and nutrients trans-
lated into diﬀerences into dietary habits, the hyposensitive sub-
jects being less likely to adopt healthy habits such as substituting
red meat with white meat and avoiding eating saturated fats.
3.2.2. Diet
Interindividual variability in fat sensing and intakemight be con-
founded by the dietary patterns of the subjects. Mattes[62] demon-
strated that the acceptability of dietary fat during a fat reduction
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program is inﬂuenced by the composition of the diet, with the
hedonic rating for high-fat foods declining in subjects deprived
of sensory exposure to fats. Later Stewart and Keast[63] showed
that subjects having consumed a low-fat diet during 4-weeks had
an increased taste sensitivity to oleic acid.
Mattes[64] has also investigated the impact of premeal fat stim-
uli on postprandial lipemia. Postprandial lipemia is a complex
process that follows biphasic kinetics. The ﬁrst phase, peaking
within the ﬁrst 30min postprandially, results from hormonal sig-
naling events preparing the organism for digestion of the meal.
This phase releases TAGs in the blood that appear to be origi-
nating from intestinal lipid stores produced by the last previous
meal. The second phase (peaking at 3–5 h) reﬂects the appear-
ance of lipid in the blood resulting from the morning meal and
de novo synthesis. Brief oral stimulation of humans with fat not
only has a signiﬁcant eﬀect on postprandial lipemia, but is also
characterized by signiﬁcant interindividual variability. In partic-
ular, Mattes[64] showed that a subgroup of subjects responded to
a 10 s oral stimulation with cream cheese, by producing a signiﬁ-
cant postprandial TAGs response after the ingestion of saﬄower
oil.
This last work illustrates the complex interactions taking place
between food and the organism, which leads to individual re-
sponses. Variability does indeed not only result from diﬀerences
in the genetic (see below) or health status of the subjects, but also
depends onmetabolic and hormonal stimulations that act within
the short-term time scale and may be signiﬁcantly inﬂuenced by
the dietary behavior of each subject.
3.2.3. Saliva Composition
Variation in the response of humans to the ingestion of FAs may
be due to diﬀerence in salivary composition. Neyraud et al.[65] in-
vestigated the variability of human saliva composition in human
subjects for a range of parameters by comparing intrasubject
variability with intersubject variability, as well as unstimulated
saliva with saliva stimulated by chewing a piece of Paraﬁlm.
For all parameters investigated the interindividual variability
was larger than the intrasubject variability. These parameters
included salivary ﬂow, protein content, lipolysis, amylolysis, pro-
teolysis, lysozyme, anti-oxidant activity, lipocalin, and uric acid.
Of note, salivary ﬂow, as well as lipolysis, lipocalin, proteolysis,
and anti-oxidant activity were stable over an 8-month period.
Similarly, fattiness perception and fat liking evidenced large
interindividual variability. Lipolysis and fat perception as well as
saliva ﬂow rate and fat liking correlated positively. In conclusion,
salivary characteristics and fat perception not only demonstrate
signiﬁcant interindividual variability, but their association sug-
gests the composition of saliva may aﬀect fat perception and
liking.
3.2.4. Body–Mass Index
Evidence that BMI might contribute to the oral sensitivity of hu-
mans to FAs was provided in 2010 by Steward et al.[60] A cohort
of healthy subjects was evaluated for sensitivity to FAs for oleic,
linoleic, and lauric acids. The hypersensitive subjects had signif-
icantly higher BMIs than the hyposensitive subjects. The same
research group later conﬁrmed these conclusions regarding the
sensitivity to oleic acid of subjects with a narrower BMI range.[61]
Stewart and colleagues[66] subsequently conducted a study in
overweight/obese and lean men to identify diﬀerence in oleic
acid sensing threshold. The detection threshold for oleic acid
was signiﬁcantly higher in the overweight/obese test group
(7.9 mmol L–1) compared to the lean group (4.1 mmol L–1). Of
note, the observed diﬀerence of 3.8mmol L–1 in themean thresh-
old for oleic acid sensing between the two BMI groups, should be
compared with the larger range of thresholds characterizing each
of the subjects in this study (1 and 12 mmol L–1). Also, this small
diﬀerence should be compared with the orders of magnitude of
diﬀerences reported between individuals in Section 3.2.2. This
shows that BMI contributes only to a minor extent to interindi-
vidual variability in fat sensing. In support to this conclusion,
Stewart and Keast[63] could not identify diﬀerences in the thresh-
old to oleic acid sensing between one group of obese/overweight
subjects and a group of lean subjects. These negative results were
later conﬁrmed by Tucker et al.[67] However, Stewart and Keast[63]
also demonstrated that a high-fat diet decreased taste sensitivity
to oleic acid in the lean group of subjects but not in the over-
weight/obese group.
Taken together, these studies suggest that the contribution of
the BMI to the interindividual variability of the oral sensibility to
FAs plays a minimal role and that this contribution is modulated
by the diet.
3.2.5. Genetic Polymorphisms
Family and twins studies, reviewed by Reed et al.,[68] revealed that
food preferences are largely determined by cultural transmission
and individual experience. Interestingly, however, fat intake is
more similar among monozygotic twins than among dizygotic
twins, suggesting that heritability does contribute to interindi-
vidual variability in fat intake.
The ﬁrst study showing an association between a gene and fat
ingestive behavior in humans was published by Keller et al.[69]
The CD36 FA translocase is a ubiquitous membrane-bound pro-
tein involved in a range of physiological immunological and
metabolic processes, including the oral detection of FAs. The
authors addressed association between ﬁve common polymor-
phisms ofCD36 and the oral detection of fat in African-American
subjects using Italian dressings prepared with varying amounts
of canola oil. A G>A variation in exon 1A (rs1761667) that re-
duces CD36 expression and is present in 45% of the subjects was
associated with an increased ability to perceive creaminess. Also,
a C>T variation in intron 11 (rs1527483) present in 12% of the
subjects was associated with an increased ability to perceive fat
content. The consideration that the ingestive behavior associated
with variants ofCD36might impact onmetabolismwas indicated
in the same study, with individuals with two (D/D) deletions at
rs3840546 (12% of the subjects) having signiﬁcant higher BMIs
than I/I homozygotes and I/D heterozygotes. Taken together, this
study provided evidence that polymorphisms in CD36 contribute
to interindividual diﬀerences in the perception of fat and, further,
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that these diﬀerences impact on body weight via regulation of
fat intake. Of note, however, the authors commented on work by
other groups reporting opposite behavior associated with CD36
polymorphisms in other populations, suggesting the existence of
additional mechanisms modulating the interindividual variabil-
ity to fat sensing associated with CD3.
The ﬁndings of Keller et al.[69] were later conﬁrmed by Pepino
et al.[70] for the rs1761667CD36 polymorphism in obese subjects.
In this study, the detection threshold for oleic acid and triolein
was signiﬁcantly (eightfold) lower for subjects homozygous for
the G allele than subjects homozygous for the A allele. Total en-
ergy, fat consumption, fat preference scores, and food cravings
were, however, similar among the diﬀerent alleles.
Genome-wide association studies (GWAS) allow for a screen-
ing and identiﬁcation of genes associated with particular pheno-
types. Tanaka et al.[71] made use of this approach, using a meta-
analysis of 12 observational studies, to identify genetic variants
associated with macronutrient intake. A variant in the chromo-
some 19 locus (rs838145) was associated with lower fat consump-
tion. A candidate gene in this region, ﬁbroblast growth factor 21
(FGF21), encodes for a hormone produced by the liver and in-
volved in lipid metabolism. Interestingly, FGF21 acts as a nega-
tive regulator of bile acid (BA) synthesis[72] and polymorphisms
in this protein might therefore contribute to interindividual vari-
ation in uptake of lipids such as cholesterol.
Further details on the genetic aspects of FA perception can be
read in the reviews by Reed and Xia[73] and Running et al.[74]
3.3. Interindividual Variability in Digestion of Fat
3.3.1. Diet
The quantity of gastric lipase excreted is inﬂuenced by the type
of meal (a high-fat diet elicits a higher output of gastric lipase
than a low-fat diet)[75] and the given period (postprandial values
are higher than fasting ones), whether in adults, children, or
infants.[39]
3.3.2. Genetic Polymorphisms
The literature does not provide strong evidence for a role of
genetic polymorphisms in fat digestion. At present, four com-
mon SNPs in CLPS (rs2766597, rs41270082, rs3748050, and
rs3748051) have been investigated but evidence for their asso-
ciation with fat intake or obesity, not fat digestion, has so far only
been provided by rodent models.[76]
3.4. Interindividual Variability in Intestinal Absorption of Fat
Usually, the entire fat digestion and absorption process lasts for
16–24 h if no more food is consumed after the initial meal.[35,77]
The gastrointestinal transit of a standardized meal, containing
33% fat (mainly from dairy products), was analyzed byMadsen[78]
in 33 healthy volunteers of both genders aged from 23 to 65 years.
Gastric emptying and intestinal transit times were not inﬂuenced
by age, sex, or BMI. The interindividual variability in gastric emp-
tying and small intestinal transit times was, however, substan-
tial; by contrast, no diﬀerence was observed between subjects in
colonic transit time. This data indicates that the factors govern-
ing interindividual variability in fat digestion are not understood
and might be of genetic origin.
3.4.1. Diet
The composition of the duodenal ﬂuids varies according to the
nutritional state (fasted or fed) and the characteristics of ingested
food. Intestinal lipid absorption has been shown to exhibit di-
urnal variations in humans, being maximized at mealtime.[79]
Notwithstanding, several parameters such as pH, lipolytic prod-
ucts, bile salts, phospholipids, osmolality, and surface tension
display ﬂuctuating patterns with high intersubject variability in
response to the same meal.[80]
Diﬀerent food components are known to reduce plasma
cholesterol levels by interfering with diﬀusion of luminal choles-
terol to the gut epithelium and/or inhibiting molecular mecha-
nisms responsible for cholesterol uptake by the enterocyte. The
capacity of soluble ﬁbers to delay cholesterol absorption, probably
via the reduction of biliary emulsiﬁcation of cholesterol and the
consequent delay of its diﬀusion from the lumen to gut epithelial
cells,[81] has been demonstrated inman.[82] A likelymechanism of
action of plant sterols is their competitionwith cholesterol for sol-
ubilization inmicelles within the intestinal lumen, thus reducing
the amount of cholesterol available for absorption, without any al-
teration of ABCG5 or ABCG8 expression in mice.[83] A reduced
saturated fat diet and a reduced saturated fat/high-ﬁber diet have
been shown to decrease cholesterol absorption by 7% and 10%,
respectively, in ileostomy subjects.[84] In cultured human entero-
cytes, eicosapentaenoic (EPA), docosahexaenoic (DHA), and PU-
FAs in general reduce cholesterol absorption by downregulating
NPC1L1 protein expression.[85,86]
The presence of dietary fat upregulates the expression of
CD36,[87] which plays a key role in the uptake of FAs.[88] McKim-
mie et al.[89] evidenced a considerable variability in the eﬃciency
of absorption of individual FAs by the healthy adult gut. Absorp-
tion eﬃciency of saturated FAs is lower than MUFAs, or PUFAs,
and is, as well, inversely correlated to the number of carbons in
the fatty acyl chains. Diﬀerent solubilization into BA mixed mi-
celles, micellar diﬀusion through the unstirred water layer, and
uptake by the enterocyte brush-border membrane could be de-
terminant of the observed diﬀerential absorption of FA, which is
not related to gender or BMI.
During fasting, the enterocytes produce mostly VLDL. In fast-
ing state, deprivation of lipid substrate causes degradation of
ApoB-48 and inhibition of nascent CM assembly. In postprandial
state, the pre-CM is transported via a pre-CM transport vesicle to
theGolgi apparatus[90] and amature CM is formed through acqui-
sition of more neutral lipids. CM production is a highly regulated
process, and postprandial plasma CM response displays a high
interindividual variability. The amount and type of ingested fat
is the major driver but other factors as non-lipid nutritional fac-
tors (carbohydrates, proteins, ﬁbers), hormones (insulin, GLP1,
GLP2), nutraceuticals, and therapeutic interventions can signiﬁ-
cantly contribute.[49]
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Overall, although food components, diet, and fasting state are
not components of the interindividual variability, they could be
confounders in nutritional studies aimed to evaluate variation in
lipid digestion, absorption, and transport.
3.4.2. CD36 Expression
Diseases that impair secretion of bile, such as biliary obstruction
or liver diseases, as well as diseases aﬀecting the secretion of pan-
creatic enzymes, such as cystic ﬁbrosis, lead to severe malabsorp-
tion of fats.[91] In patients with liver cirrhosis, upregulation of in-
testinal glycosylated CD36 causes rapid absorption of LCFAs.[92]
3.4.3. Circadian Rhythm
Diurnal variation[93] linked to fasting and postprandial states[94] of
BA synthesis rate also contributes to variability of absorption of
dietary lipids. CM production undergoes diurnal variation, with
concentration highest at night after feeding. This is coupled to
changes in the gene expression of key proteins including MTP
and ApoB, and disruptions in circadian rhythms have been pro-
posed to contribute to dyslipidemia and insulin resistance.[95]
3.4.4. Body–Mass Index
Secretion of CCK and other gastrointestinal hormones, which is
induced by cell surface receptor signaling stimulated by FAs,[96,97]
is aﬀected by BMI. Little et al.[98,99] found an inverse correla-
tion between the number of CCK-immunoreactive cells and BMI,
which conﬁrms that the gastrointestinal hormone responses to
fats are attenuated in obesity, leading to impaired energy intake
regulation with subsequent weight gain.
3.4.5. Genetic Polymorphisms Aﬀecting Cholesterol Absorption and
Serum TAGs
Interindividual variability is thought to also be due to genetic fac-
tors likely involving numerous genes implicated in lipid absorp-
tion, secretion, and clearance.
Given the fact that dozens of proteins are involved in BA syn-
thesis and handling in the mammalian system, it can be an-
ticipated that there are also numerous genetic factors underly-
ing variability in BA proﬁle and physiological processes sensitive
to BA, including cholesterol absorption. Cholesterol absorption
may also be modulated by the mucous coating the intestinal mu-
cosa. Mucous is a diﬀusion-limiting barrier, especially for choles-
terol that may be extensively bound to surface mucins prior to
transfer into the enterocyte. Physiological quantities of epithelial
mucin are necessary for normal intestinal uptake and absorption
of cholesterol in mice.[100] Several polymorphisms in genes en-
coding for intestinalmucin have been identiﬁed, but their impact
on intestinal absorption is still unknown.
Intestinal permeability and colon transit are aﬀected by intra-
luminal BA. In particular, the G protein-coupled bile acid recep-
tor 1 (GPBAR1), which is expressed in the enteric nervous system
and the enteroendocrine cells, has been demonstrated to medi-
ate the prokinetic actions of BAs in a murine model.[101,102] In
humans, there is evidence that genetic variation in GPBAR1 af-
fects colon transit and total excretion of fecal BAs, predisposing
aﬀected subjects to irritable bowel syndrome (IBS).[103]
ACAT2 expression is restricted to the small intestine and
liver,[104] and its deﬁciency reduces cholesterol absorption ren-
dering mice resistant to diet-induced hypercholesterolemia,
gallstone formation, and atherosclerosis.[105,106] He et al.[107]
showed that, in humans, three ACAT2 polymorphisms, 41A>G
(Glu>Gly), 734C>T (Thr>Ile), and IVS4-57_58 ins48 bp (D/I),
associate with plasma lipid levels and coronary artery disease
(CAD) susceptibility, but that their eﬀects were not consistent
across genders and ethnic groups. In a further study, the en-
zymatic activity of mutant Glu(14)Gly was found approximately
two times higher than the wild-type activity and was associ-
ated to plasma lipid levels and CAD risk.[108] ACAT2 expres-
sion is restricted to the small intestine and liver,[104] and its de-
ﬁciency reduces cholesterol absorption rendering mice resistant
to diet-induced hypercholesterolemia, gallstone formation, and
atherosclerosis.[105,106]
An allele of the FABP-2 promoter consisting of three polymor-
phisms located within 110 bp 5′ of the transcription initiation
site has been described by Geschonke et al.,[109] who evidenced an
inﬂuence of the promoter polymorphism on the kinetics of the
postprandial increase of TAGs. Another human genetic variant in
FABP-2, in which an alanine at codon 54 is substituted by a threo-
nine, is associated with increased postprandial plasma TAGs.[110]
Increased excretion of TAGs in the feces of pPLA2-KO mice on
a high-fat diet indicates that pPLA2 deﬁciency has a greater ef-
fect on the absorption of TAGs than PL hydrolysis,[111] which is
probably compensated for by other phospholipases.[112] Polymor-
phisms in CD36 are associated with plasma vitamin E[113] and
carotenoid concentrations in humans.[114] At present, the eﬀect
of CD36 variation on FA absorption has not been investigated. It
is worth noting that in CD36 null mice there is a defect in the
free FA uptake by the proximal intestine, which is compensated
for by uptake in the distal intestine.[115]
As observed in MGAT2 or DGAT1 knockout animals, varia-
tion in MGAT and DGAT seems to have no eﬀect on overall fat
absorption but it delays transport of CMs into circulation.[116]
Intestine-speciﬁcMTP ablation signiﬁcantly reduces cholesterol
absorption in mice.[117] Mutations in the coding region of MTP
have been reported to abolish the production of apoB-containing
lipoproteins and to lead to abetalipoproteinemia.[118] Among
the SNPs in MTP, the −493G/T in the promoter region has
been mostly studied due to its plausible role in the modulation
of lipid/lipoprotein proﬁles.[119] Most but not all investigators
reported an association between the MTP-493T allele and low
levels of serum total cholesterol (TC), LDL-C, and apoB. The
underlying reasons for the discrepancy in these ﬁndings might
relate to diﬀerences in the populations studied, including dif-
ferences in the diet.[120] In MTP I128T SNP, the T128 variant
confers reduced structural stability and decreased binding ca-
pacity to LDL particles. In Northern Europeans, the T128 allele
is associated with lower plasma levels of TC and LDL-C.[121] This
allele has been found to be protective against hyperlipidemia also
in Chinese people.[122] Another MTP polymorphism, Q297H, is
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associated with lipid homeostasis. Carriers of homozygous mi-
nor allele (297H) have signiﬁcantly lower LDL-C and non-HDL-C
but higher risk for nonalcoholic fatty liver disease (NAFLD).[123]
Also carriers of a loss of function variant, (rs58542926, resulting
in a glutamate to lysine substitution at residue 167) in TM6SF2
have an increased susceptibility to NAFLD with low circulating
lipids.[124] O’Hare et al.[125] evidenced in two human cohorts that
carriers of this TM6SF2 variant had improved fasting lipid pro-
ﬁles. In one cohort, variant carriers also exhibited signiﬁcantly
lower postprandial serum TAGs, suggestive of a role for TM6SF2
in the small intestine.
Familial hypobetalipoproteinemia, an autosomal codominant
disorder, is characterized by molecular defects in APOB. Numer-
ous polymorphisms of APOB have been described with an eﬀect
on lipid levels and cardiovascular risk. Nevertheless, not one of
these associations has been consistently observed in a large num-
ber of studies, probably due to diﬀerences of ethnic groups and
environmental factors.[126]
Finally, Desmarchelier et al.[127] evaluated a combination of
SNPs associated with the postprandial CM response in 33 healthy
male volunteers. In this population, most of the interindividual
variability in the postprandial CM response to dietary fat could be
explained by a combination of 42 SNPs in 23 genes. Although it
is likely that other genes as well as epigenetic factors are involved
in the interindividual variation of postprandial CM response, this
study clearly highlights the complexity of the problem.
3.4.6. Genetic Polymorphisms Aﬀecting Phytosterol Absorption
Phytosterols (PSs) are plant sterols structurally similar to choles-
terol. As such the genetic polymorphisms impacting on the ab-
sorption of fat, may also modulate processing of PSs by the
GIT. As reported above, variability in plasma PS concentration
among individuals is a reﬂection of either dietary intake and/or
PS handling.[128–130] As demonstrated in large cohorts, plasma
PS concentration varies within a ﬁve- to tenfold range among
individuals,[131,132] with the diﬀerences in variability remaining
stable over time for a given individual.[133] In studies where di-
etary intake of PSs has been controlled, wide interindividuality
in plasma PS concentrations has been established and repeat-
edly demonstrated,[134] indicating interindividual variability in PS
handling.[135]
The genetic proﬁle has been demonstrated to account for 80%
of the variability.[133] To date the majority of research attempting
to identify genetic variability as justiﬁcation for interindividuality
in plasma PS concentration has focused on identifying SNP in
genes encoding for ABCG5, ABCG8, and NPC1L1.
Functionally severe mutations in genes encoding for ei-
ther ABCG5 or ABCG8 transporters, results in the rare lipid
metabolic disorder, phytosterolemia. As ABCG5 or ABCG8
regulate intestinal sterol via eﬄux, this condition is charac-
terized by hyperabsorption and decreased biliary excretion of
dietary sterols. ABCG5 and ABCG8 favor PS transport, as such
30–100-fold increases in non-cholesterol sterols within plasma
can be observed in people with phytosterolemia.[136,137] Although
phytosterolemia is representative of an extreme case, more com-
mon sequence variants in ABCG5 or ABCG8 may have more
subtle eﬀects on sterol metabolism and contribute to interindi-
vidual variation in the plasma concentrations of PSs. Although
research within this area is currently limited due to a preferential
focus on cholesterol handling with these transporters, several
polymorphisms for both ABCG5 (Q604E) and ABCG8 (T400K,
D19H, M429V, and A632V) have been investigated in relation to
PS handling.
Limited work has investigated the ABCG5 polymorphism,
Q604E. Gylling and colleagues,[138] in a cohort of 263 (114 male,
119 female; 53.1 ± 0.5 years) mild to moderate hypercholes-
terolemic subjects (serum cholesterol < 7.5 mmol L–1), iden-
tiﬁed that the Q604E polymorphism was signiﬁcantly associ-
ated with low serum sitosterol in men. However, interestingly
this was not seen in women. Q604E has additionally been in-
vestigated in relation to identifying an association with both
cholesterol-standardized serum campesterol and sitosterol con-
centrations, and changes in serum PS concentration after con-
sumption of phytostanols. However, the ABCG8 polymorphism
T400K demonstrated themost signiﬁcant relationship with these
two variables in comparison with the ABCG5Q605E and ABCG8
A632V polymorphisms.[139]
In further regard to the ABCG8 polymorphism T400K, within
the same study, additional analysis by Plat et al.[139] evaluated
the association between the three diﬀerent alleles of the ABCG8
T400K polymorphism (TT, TK, and KK). The researchers found
that the TT genotype had the largest reduction in serum PS con-
centration during consumption of phytostanols esters. This is in-
dicative that the functionality of the ABCG5/G8 heterodimer is
reduced in subjects with the TT genotype compared to TK and
KK genotypes. In addition, interestingly this relationship was ob-
served with no relationship with serum lipid and lipoprotein con-
centrations, suggesting that changes in the reduced functionality
of the ABCG5/G8 heterodimer in the TT genotype,mainly aﬀects
plasma sterol concentrations, but not cholesterol.
The ABCG8 polymorphism T400K, in exon 8, as well as the
ABCG8 D19H polymorphism in exon 1 have been shown to have
the most pronounced eﬀects in interindividuality, with these two
sequence variations (D19H and T400K) being associated with
lower serum phytosterol concentrations in a normolipidemic
populations, indicating lower sterol excretion.[133]
The D19H polymorphism has been associated with lower
serum campesterol and sitosterol than subjects without the al-
lele in both normal and hypercholesterolemic subjects (serum
cholesterol < 7.5 mmol L–1).[133,138,140] This ﬁnding has also
been reﬂected within a systematic review and meta-analysis
of ABCG5/G8 polymorphisms and markers of cholesterol
metabolism.[141] Within a pooled dataset of four studies, Jakulj
and colleagues[141] reported that the ABCG8 D19H polymor-
phism results in decreased total plasma PS concentration. In-
terestingly, the prevalence of the D19H polymorphism has been
found to be rare in Asian and particularly Japanese populations,
in addition to the ABCG8 SNP A632V. This was highlighted by
Miwa and colleagues,[142] when drawing comparisons between
Japanese and Caucasian populations.
Within the same study by Miwa and colleagues,[142] a novel
ABCG8 polymorphism, M429V, was identiﬁed, within a popula-
tion of Japanese hypercholesterolemic patients (n = 100, 48 men
and 52 women, aged 30–87 years). The researchers found that in-
dividuals with theM429Vpolymorphismhad signiﬁcantly higher
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sitosterol serum levels, than non-carriers. To our knowledge, this
is the only study to have identiﬁed and investigated the M429V
polymorphism in relation to PS metabolism to date.
Signiﬁcantly less has been investigated in NPC1L1 related
polymorphisms than ABCG5/8, with the majority of work inves-
tigatingNPC1L1 polymorphisms in relation to cholesterol. How-
ever, non-synonymous sequence variations inNPC1L1 have been
shown to be ﬁve timesmore common in low absorbers of sterols,
including PS, than in high absorbers.[143] Which of the sequence
variations were associated with lower absorption, however, was
not identiﬁed. Further work to identify speciﬁc NPC1L1 related
SNP, and their relation to PS absorption and metabolism is thus
clearly required.
4. Carbohydrates
4.1. Overview of Carbohydrate Processing by the GIT
Based on their chemical structure carbohydrates can be grouped
in monosaccharides and disaccharides (both commonly re-
ferred to as sugars), oligosaccharides (composed of malto-
oligosaccharides and nondigestible oligosaccharides), polysac-
charides (composed of starch and non-starch polysaccharides
polyols) and sugar alcohols.[144] The most common carbohy-
drates in foods are glucose and fructose (among themonosaccha-
rides), sucrose and lactose (disaccharides), raﬃnose, stachyose,
and fructo-oligosaccharides (oligosaccharides), starch, cellulose,
hemicellulose, pectin, 𝛽-glucans, fructans, mucilages, and algal
polysaccharides (polysaccharides), and sorbitol, mannitol, xylitol,
lactotol, and maltotol (sugar alcohols).[145]
After carbohydrates are ingested, chewed, andmixed with sali-
vary amylase, among others salivary juices, the bolus is swal-
lowed and passed to the stomach through the esophagus. Once
in the stomach, the acid neutralizes the salivary amylase halting
further digestion of the carbohydrates and the chyme is formed.
After the stomach, the chyme enters the small intestine and the
duodenum. The pancreas releases the enzyme pancreatic amy-
lase, which breaks the polysaccharides down into disaccharides.
Afterward, enzymes such as lactase, and maltase break down the
disaccharides into monosaccharides, which are then absorbed in
the small intestine.[146]
Carbohydrates can be classiﬁed based on their digestion and
absorption in the small intestine.[144] Digestible carbohydrates
are digested and absorbed in the small intestine whereas nondi-
gestible carbohydrates (referred to as dietary ﬁbers) are not
digested by the small intestine and reach the large intestine to
be fermented by the colonic microbiota. Glucose and fructose
are thus absorbed directly into the capillaries within the villi of
the small intestine. Most of the blood glucose is not stored in the
liver but rather, via the action of insulin, rapidly passes through
to the muscle and adipose tissue. Fructose, independently of
insulin, converts in the liver to glucose, lactate, and/or fatty acids
before passing into the blood stream where it can be oxidized
for energy in other tissues.[147] Therefore, fructose is considered
a less direct source of energy. Di-, oligo-, and poly-saccharides
must be hydrolyzed tomonosaccharides to be absorbed. Fructose
is, thus digested in the small intestine by sucrase to produce
glucose and fructose. Similarly, lactose is digested by lactase in
the small intestine to produce glucose and galactose. The diges-
tion of oligosaccharides and polysaccharides is more complex,
the contribution of the small and large intestine depending on
the physico-chemical property of each carbohydrate. For some
of these carbohydrates (e.g., maltodextrin), the combination
of amylases with enzyme cleaving disaccharides (maltase, su-
crase, isomaltase, lactase) is suﬃcient to complete digestion
and absorption of the resulting monosaccharides in the small
intestine. Others carbohydrates cannot (e.g., carbohydrates con-
taining glycosidic linkages) or only partially (e.g., the digestible
fraction of starch) be digested by the small intestine. These
molecules are therefore fermented to various degrees by the
colonic microbiota.[144] Of note, oligo- and polysaccharides are
considered more satiating than sugars because of their eﬀect on
processes such as gastric emptying and their transformation into
short chain fatty acids (SCFAs), which can increase the secretion
of hormones and peptides from enteroendocrine cells that result
in increased satiety.[147] Finally, sugars alcohols are not processed
by the intestinal digestive system and are absorbed directly, al-
though to diﬀerent extents, into the circulation. Although some
sugar alcohols, such as erythrytol are absorbed unmodiﬁed,
others, such as lactitol, are fermented by the colonic microbiota
prior to absorption.[148]
Factors that are likely to have an impact on interindividual
diﬀerences in the response of humans to carbohydrate inges-
tion, as illustrated by the variability in the postprandial glycemic
response,[149] are numerous, including genetics, lifestyle, insulin
sensitivity, exocrine pancreatic, sugar transporters activity levels,
oral processing, and human gut microbiome composition. How-
ever, clear evidence for this interindividual variability has only
been documented for a small number of dietary carbohydrates.
Among the variables presented in the last paragraph of the In-
troduction, a search of the literature has identiﬁed convincing ev-
idence for interindividual variability in oral processing, digestion,
and intestinal absorption of carbohydrates by the GIT for the fol-
lowing variables: chewing, genetic polymorphisms, and gut mi-
crobiota.
4.2. Interindividual Variability in Oral Processing
of Carbohydrates
4.2.1. Chewing
Chewing mechanically breaks down complex carbohydrates in
the mouth and salivary amylase, secreted by the salivary glands,
breaks down the starches into the disaccharide maltose. The de-
gree of mastication diﬀers signiﬁcantly among individuals and
may contribute to the signiﬁcant interindividual variation ob-
served in the glycemic response to a food, due to the impact it
has on food structure, and speciﬁcally particle size (see also the
section on proteins).
A suitable example of this is the work by Zhu et al.,[150] who
identiﬁed that the elderly require a greater number of chews to
form a bolus before swallowing, and investigated the impact of
this chewing behavior on glucose metabolism. In a randomized
cross-over trial, comparing 15 with 40 chewing movements be-
fore swallowing, plasma concentrations of glucose, insulin, and
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gastric inhibitory peptide (GIP) were signiﬁcantly higher when
40 chews weremade, with late postprandial period becoming sig-
niﬁcantly lower. Their results suggested that increased number
of chews within the oral phase, controlled glucose metabolism
post-oral processing by modulating the release of glucose in
the blood. Looking speciﬁcally at chewing on food structure,
Ranawana et al.[151] studied the impact of food particle size on
gastric emptying and the glycemic response. Within this study,
smaller particles caused a signiﬁcantly greater glycemic response
than the larger particles. The insulin response was also signiﬁ-
cantly greater for the small particles than the large particles. The
gastric emptying latency phase, lag, and half-time were signiﬁ-
cantly shorter for the small particles. As such, smaller particles
were identiﬁed to produce faster gastric emptying and greater
glycemic and insulin response. Furthermore, Ranawana et al.[152]
used rice as the model to establish if interindividual variances in
mastication and resulting degree of particle breakdown had an
impact on in vitro and in vivo glycemic potency. In a randomized
crossover design, with 15 subjects, the particle size distribution
and in vitro digestibility of individuals’ chewed rice were estab-
lished together with their in vivo blood glycemic response. The
content in rapidly digested starch in themasticated boluses, were
measured during in vitro digestion. The particle size distribution
of masticated rice varied signiﬁcantly between participants. In
vitro digestion of rice diminished as particle size increased. The
degree of particle size breakdown, as a result of mastication, cor-
related with the content in rapidly digested starch in the chewed
food bolus and initial digestion rate in vitro. The amount of undi-
gested food remaining at the end of 120-min in vitro digestion as-
sociated signiﬁcantly with the percentage of particles greater than
2000 µm in masticated rice. The percentage of particles smaller
than 500 µm correlated signiﬁcantly with the in vivo glycemic
response at 30 min post-ingestion, although not with the total
incremental area under the blood glucose curve. The gradation
of usual mastication could consequently potentially aﬀect both
the scale and pattern of the glycemic response and may partially
explain their interindividual diﬀerences. However, despite such
ﬁndings, when all the food related factors including ingested par-
ticle size (mastication) are controlled for, interindividual varia-
tions in the glycemic and insulin response have still been ob-
served which suggests additional factors than just oral process-
ing contribute to interindividual diﬀerences in the glycemic re-
sponse.
4.3. Interindividual Variability in Digestion of Carbohydrates
4.3.1. Genetic Polymorphisms and Amylase Copy Numbers
Low serum amylase (hypoamylasemia) has been described in
certain common cardiometabolic diseases such as diabetes and
metabolic syndrome. All of these diseases appear to have a
common etiology of inadequate insulin activity due to insulin
resistance and/or reduced insulin secretion. Some clinical stud-
ies have indicated that salivary amylase may be preferentially
diminished in obese individuals, while others have shown that
pancreatic amylase may be preferentially reduced in diabetic
subjects with insulin dependence. Obesity, as a condition that
elicits cardiometabolic diseases relating to insulin resistance
(major contribution), may actually be a common determinant
for low serum amylase in a general population.[153] However,
regardless of the accumulated evidence, the clinical relevance
of serum, salivary, and pancreatic amylase and the underlying
mechanisms have not been fully clariﬁed.[153]
The genes encoding for 𝛼-amylase are positioned in a cluster
on the chromosome that comprises of the salivary amylase gene
(AMY1), two pancreatic 𝛼-amylase genes (AMY2A and AMY2B),
and an associated pseudo gene. AMY1 displays a copy number
variation (CNV), which is directly proportional to the salivary
𝛼-amylase amount in saliva.[154] Populations that evolved under
high-starch diets versus low-starch diets possess a higher aver-
age copy number of AMY1, which reveals an intense positive
selection imposed by diet on amylase copy number during evo-
lution. The impact of CNV of AMY1 on human metabolism is
broad involving evolutionary aspects of diet-gene interaction, the
glycemic response after starch consumption, the modulatory ac-
tion of 𝛼-amylase inhibitors on starch digestion, eﬀects on taste
perception and satiety, and inﬂuence on psychosocial stress. Also,
other factors, such as hydration status, psychosocial stress level,
and short-term dietary habits also inﬂuence the 𝛼-amylase con-
tent in saliva, all contributing to intraindividuality.[154]
Haplotypes diﬀer in their structure based on the odd or even
content of AMY1, which in turn is coupled to the copy number
of pancreatic AMY2A and AMY2B.[155] Most haplotypes have one
copy each of AMY2A and AMY2B and have an odd number of
copies ofAMY1. In contrast, haplotypes carrying an even number
ofAMY1 have rearrangements causing CNV ofAMY2A/AMY2B.
Human populations possess diﬀerent proportions of the basic
haplotype classes.[155] CNVs in AMY1, which varies more largely
than the pancreatic amylase gene (AMY2A and AMY2B), corre-
lated well with salivary and serum amylase levels. Additionally,
low CNV of AMY1, indicating low salivary amylase, was linked
with low taste perception/satiety insulin resistance, postprandial
hyperglycemia, and obesity.
4.4. Interindividual Variability in Intestinal Absorption
of Carbohydrates
4.4.1. Genetic Polymorphisms and Lactose Intolerance
Lactose intolerance is a frequent digestive problem. If the lac-
tase enzyme is absent (alactasia) or deﬁcient (hypolactasia), undi-
gested lactose reaches the colonic microbiota, resulting in the
production of SCFAs, hydrogen, and methane.[156]
Lactose intolerance might be genetic (primary hypolactasia
and primary congenital alactasia) or environmentally induced
(secondary or acquired hypoalactasia). In both cases, symptoms
are produced by deﬁcient levels of lactase in the lining of the
duodenum.[157] In the situation of primary or secondary lactase
shortage, lactose passes throughout the GIT undigested or partly
digested by enzymes generated by the intestinal bacterial ﬂora. As
a result, the undigested lactose molecules and products of bacte-
rial digestion cause symptoms of lactose intolerance, such as ab-
dominal pain, ﬂatulence, gas, bloating, and diarrhea.[158] The bi-
ological mechanisms leading to lactose malabsorption have been
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Figure 2. Postprandial kinetics of the lactose-derived metabolites galactonate (left) and galactitol (right) in the serum of subjects having ingested
acidiﬁed milk. The relative intensities of galactonate and galactitol were measured by GC–MS. The red lines represent subjects with the CC genotype
at the MCM6 rs49882359 allele. The orange lines represent subjects with the CT genotype. The green lines represent subjects with the TT genotype.
Adapted from Vionnet et al.
well described within numerous investigations, and several ge-
netic, endoscopic, and physiological diagnostic tests are available.
Lactose intolerance depends not only on insuﬃcient lactase en-
zyme, but also on the amount of lactose, gastrointestinal motility,
intestinal ﬂora, small intestinal bacterial overgrowth, and sensi-
tivity of the GIT to the formation of gas and other fermentation
products of lactose digestion. The intestinal lactase activity nor-
mally decays in children, although approximately one-third of hu-
mans now retain this activity during their life time.[158]
Lactase persistence (LP) is now common mainly in people
of northern European descent and is due to the inheritance of
autosomal-dominant polymorphisms that prevent the epigenetic
decline in lactase expression during childhood. The identiﬁca-
tion of genetic variants linked with LP or lactase non-persistence
(LNP) permits molecular recognition of the genetic predisposi-
tion of adult-onset hypolactasia by DNA sequencing or restric-
tion fragment length polymorphism analysis.[158] Lukito et al.[159]
established that many individuals of European ancestry with the
hereditary LP possess the C/T-13 910 SNP in allele rs49882359
ofMCM6, a gene that regulates the expression of the lactase LCT
gene. Other lactase persistent populations are found in Africa
and the Middle East with diverse genetic variants. These SNPs
mirror the nutrient-dependent ecological adaptation that took
place as an evolutionary consequence of the agricultural revolu-
tion, which included dairying practices. This said, the gastroin-
testinal symptoms due to lactose malabsorption in the small
intestine correlate, although not always clearly, with LNP. The
lactose-hydrolyzing activity of the colonic microbiome allows lac-
tose fermentation to take place, so that the disaccharide is, conse-
quently, not found in feces. The production of SCFAs and gases
(carbon dioxide, hydrogen, methane), which can lead to the on-
set of symptoms, are also dose dependent. Up to 25 g of lactose
can typically be consumed by individuals with LNP. However, the
food matrix, dietary pattern, characteristics of the microbiome,
age, as well as other factors are likely to alter tolerance. Hence,
the idea that lactose intolerance is a disorder or disease of indi-
viduals with LNP is ﬂawed and contains a cultural perspective.[159]
Interindividual variability in the metabolism of lactose has re-
cently been demonstrated by Vionnet et al.[156] who measured
metabolites derived from lactose in the blood and urine of hu-
man adults subjects having ingestedmilk. These authors showed
that not only lactose, but also galactose and two liver metabolites
derived from galactose, galactitol, and galactonate demonstrated
signiﬁcant interindividual variability. In particular, a bimodal dis-
tribution of the postprandial kinetics of galactonate and galac-
titol in serum was observed in serum after milk ingestion (i.e.,
high responders and low responders; Figure 2). In 92% of the
cases, the galactonate and galactitol responses matched the LCT
genotype at rs4988235 for lactase persistence. The remaining 8%
were proposed to reﬂect subjects whose lactose metabolism was
misclassiﬁed based on genetic testing. The authors therefore pro-
posed that the measurement of these metabolites after a lactose
overload could be a better marker of lactase activity.
Themanagement of lactose intolerance comprises of a lactose-
reduced diet and enzyme substitutes. This approach is eﬀective if
symptoms are independently associated to dairy products. How-
ever, lactose intolerance can be part of a bigger intolerance to
variably absorbed, fermentable oligo-, di-, monosaccharides, and
polyols (FODMAPs). This phenomenon is observed in at least
half of the patients with irritable bowel syndrome (IBS), who
then need not only to control their lactose intake but also to
decrease their dietary FODMAPs to recover from gastrointesti-
nal symptoms. Of note, the long-term eﬀects of a dairy-free, low
FODMAPs diet on nutritional health and the fecal microbiome
of humans are unclear.[157]
4.4.2. Genetic Polymorphisms and Fructose Malabsorption
Fructose is absorbed in the small intestine via the glucose
transporter (GLUT) 5, which possesses a limited capacity of ab-
sorption, and transported into the blood by GLUT2. Fructose can
be metabolized in the small intestine and liver by enzymes such
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as fructokinase, aldolase B, and triokinase.[160] Carbohydrate
response element-binding protein (ChREBP) is a transcription
factor involved in glycolytic and lipogenic gene expression
linked to carbohydrate consumption. ChREBP target genes are
implicated in fructolysis (Glut5, fructokinase), glycolysis (Glut2,
liver pyruvate kinase), and lipogenesis (acetyl CoA carboxylase,
fatty acid synthase).[160]
A deﬁciency in ChREBP may be responsible for fructose in-
tolerance, as it impairs fructose transport and metabolism, when
there is excessive consumption of fructose.[161] Additionally, de-
fects in fructose transporters like GLUT5 and GLUT2 and re-
duced expression of the genes involved in fructose metabolism,
are likely to be other causes of fructose malabsorption.
4.4.3. Genetic Polymorphisms and Glucose Transport
Vega Lopez et al.[162] compared the glucose response of healthy
adults elicited on three diﬀerent occasions after the consumption
of 50 g of available carbohydrate, bread, and glucose, and con-
cluded that the intraindividual responses between participants
diﬀered by 43%. These authors also mentioned that understand-
ing all the sources of variability would be helpful in better deﬁn-
ing the utility of glycemic index values.
One source of interindividual variability could be genetics.
The sodium/glucose co-transporter (SGLT)-1 protein is a rate-
limiting factor for absorption of glucose and galactose in the
small intestine, and it uses transmembrane sodium gradients to
drive the cellular uptake of thesemolecules. Mutations on SGLT1
(missense, nonsense, and frameshift) can lead to wakened cellu-
lar glucose transport and cause glucose–galactose malabsorption
(GGM). In the general population, the functional consequences
of variants related to intestinal glucose absorption are unchar-
acterized. Seidelmann et al.[163] therefore attempted to identify
SGLT1 variants and to describe their clinical consequences. Sei-
delman et al.[163] concluded that missense variants in SGLT1 pro-
tect from diet-induced hyperglycemia in numerous populations.
Reduced intestinal glucose uptake may protect from long-term
cardiometabolic outcomes, providing support for therapies that
target SGLT1 function to prevent and treat metabolic conditions.
4.4.4. Gut Microbiota
Human digestive enzymes are not able to break downmost com-
plex carbohydrates and plant polysaccharides. As an alternative,
these polysaccharides are metabolized by microbes, which gen-
erate SCFAs, as a by-product of fermentation of these complex
carbohydrates including acetate, propionate, and butyrate, which
can be utilized as energy source by the body.[164] It is well rec-
ognized that dietary intake of non-digestible carbohydrates af-
fects microbial fermentation and total bacterial numbers in the
colon. New evidence from molecular ecology has also revealed
that the total and type of non-digestible carbohydrates (e.g., re-
sistant starch, non-starch polysaccharides, and prebiotics) inﬂu-
ences the species composition of the intestinal microbiota both
in short-term dietary interventions and in answer to usual long-
term dietary intake. Interindividual variation in gut microbiota
might, partially, indicate diﬀerences in dietary intake, but the re-
sponse of the gut microbiota to dietary change can also vary be-
tween individuals.[165]
Among the numerous genes that have been identiﬁed in
the human gut microbiome, those that encrypt carbohydrate-
active enzymes are of speciﬁc interest, as these enzymes are
mandatory to digest most of our complex collection of dietary
polysaccharides.[166]
Zeevi et al.[149] showed that an algorithm combining personal
clinical and microbiome features, could predict the postprandial
glucose response of human subjects to the ingestion of food.
Further, this algorithm was successful to propose a personalized
dietary plan able to lower the postprandial glycemic response
in an independent cohort of 26 subjects. To develop the algo-
rithm, 46 898 postprandial glycemic responses were measured.
The responses were highly variable among the individuals even
when they consumed the same standardized meals. Of note, the
glycemic response is also characterized by a signiﬁcant intrain-
dividual variability.
The presence of Proteobacteria and Enterobacteriaceae in the
GIT is linked to poor glycemic control, and with diseases related
to metabolic syndrome such as obesity, insulin resistance, and
impaired lipid proﬁle.[167] Actinobacteria associations diﬀer as
Zeevi et al.[149] found a positive association with the postprandial
glycemic response to both glucose and bread, while Wu et al.[168]
reported that this phylum is associated with a high-fat, low-ﬁber
diet.
The diversity of the gut microbial composition is reduced in
approximately all modern chronic conditions studied.[169] The
“Western diet,” rich in animal protein, fats, and artiﬁcial ad-
ditives, and deﬁcient in ﬁber, beneﬁcial microbes, plant phyto-
chemicals, vitamins, and minerals, is considered to drive this de-
crease in gut microbial diversity by promoting gut dysbiosis, a
situation in which one or more potentially harmful microorgan-
isms are predominant, therefore, creating a disease-prone situa-
tion. Recent dietary intervention studies indicate that diets rich
in plant-based, simply processed ﬁber could quickly reverse the
eﬀects of meat-based diets on the gut microbiome.[169] However,
despite the clear evidence for the impact of diet on the gut mi-
crobiome, host genetics as well as the diversity and complexity
of the gut microbiome might impair its dietary modulation on a
personalized base.[169]
As detailed above, a large number of human intervention
studies have conﬁrmed that the nutritional behavior can lead
to statistically signiﬁcant changes in the composition of the gut
microbiota. Roberfroid et al.[170] showed that changes in the mi-
crobiota composition, in particular increases in Biﬁdobacteria,
are indicators of intestinal health. Food products that cause a
selective change in the gut microbiota composition and activity
strengthen normobiosis and produce important physiological
eﬀects in the colon and in extra-intestinal compartments leading
to reduced risk of intestinal and systemic pathologies.[170] Despite
the fact that numerous factors shape the microbial composition
of the colon, the diet remains an important factor because most
microorganisms in the colon obtain energy for their growth by
degrading and absorbing complex dietary compounds, partic-
ularly dietary ﬁbers. Non-digestible carbohydrates that bypass
digestion in the upper GIT have a broad range of structures
whose diversity has not yet been completely appreciated, in
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particular with regards to their metabolism by the gut bacteria.
In that regard, Hamaker and Tuncil[171] introduced the concept
that individual chemical structures, often contained in ﬁber
molecules, are speciﬁcally recognized by metabolic gene clusters
in bacterial genomes. The large number of structural variations
in dietary ﬁbers is due to multiple genetic and environmental
factors including the anatomical structure of the grain or plant
from which the ﬁbers are derived, the macro-organization of
the ﬁber polymers, or the size distribution of the carbohydrates
in oligosaccharides and small polysaccharides. The structural
complexity of dietary ﬁbers could allow bacteria to survive in the
aggressive colonic environment.[171]
5. Vitamins
5.1. Overview of Vitamin Processing by the GIT
Although only required in small amounts, vitamins are essential
nutrients whosemain task is to participate in controlling catalytic
functions involved in metabolism. Based on their solubility, they
have been categorized as water (B and C vitamins) and fat-soluble
(vitamins A, E, D, K). Only in some individual cases (retinol, cal-
ciferol and niacin) is the human body able to synthesize the vi-
tamin from corresponding precursors, the provitamins. For all
other vitamins, their intake through diet is essential.[8,172] Vita-
mins are mainly absorbed in the upper two parts of the small
intestine, the duodenum and the jejunum. The duodenum is the
main absorption site for vitamins A, B1 (thiamin), B2 (riboﬂavin),
B3 (niacin), B7 (biotin), B9 (folate), and the lipid soluble vitamins
D, E, and K. To a lesser extent, these vitamins are also absorbed
in the jejunum, which is the main absorption site for B5 (pan-
tothenic acid) and B6 (pyridoxine). In the distal part of the small
intestine, the ileum, vitamin B12 and vitamin C are absorbed, as
well as to a lesser extent folate and vitamins D and K.[173] Some vi-
tamins like B1 (thiamine), B2 (riboﬂavin), B7 (Biotin), B9 (folate),
and vitamin K are also produced by the large intestinal bacteria,
and therefore the colon is another possible site of absorption of
this vitamins.[174–176]
The GIT is separated from the circulatory system by a multi-
layer of epithelial and other cells, which impede the vitamins to
pass this epithelial wall. In humans and animals, the transport
of vitamins across the small intestine is biphasic: mainly by
active transport via speciﬁc carriers at low concentrations, and
predominantly by passive diﬀusion down the osmotic gradient at
higher concentrations.[8,177] Intestinal transport occurs either via
carrier-mediated Na+ dependent mechanisms (e.g., biotin, pan-
tothenic acid) or via an acidic pH-dependent, Na+-independent
carrier-mediated mechanism (e.g., vitamin B6, riboﬂavin).[8,174]
The lipid-soluble vitamins A, D, E, and K are incorporated into
CMs with other lipids and absorbed by the mucosa cells of
the small intestine.[8,172] It was long assumed that fat-soluble
vitamins are absorbed by passive diﬀusion across the plasma
membrane of enterocytes. However, new ﬁndings indicate
that several membrane transporters, which play a key role in
intestinal absorption of cholesterol, can also transport vitamin A
and E.[178]
Water-soluble vitamins are not stored, except for cobalamin.
If the intake exceeds the requirements, most of the vitamin
excess is excreted by urine and feces. In contrast, lipid-soluble
vitamins may be stored in signiﬁcant amounts in the liver and
fat tissue.[172]
Among the variables presented in the last paragraph of the In-
troduction, a search of the literature has identiﬁed convincing ev-
idence for the interindividual variability of the intestinal absorp-
tion of vitamins by the GIT for the following variables: genetic
polymorphisms.
5.2. Interindividual Variability in Intestinal Absorption of Vitamins
Literature reports an interrelationship between genetic polymor-
phism and vitamins. On the one hand, mutations may result
in a modiﬁed vitamin bioavailability and intake; on the other
hand, many vitamins inﬂuence genome expression, stability, and
viability[179] e.g., deﬁciencies impair nucleotide biosynthesis and
thereby enhance polymerase error rates like single point muta-
tions or DNA strand breaks. However, few gene variants are suf-
ﬁciently penetrant to aﬀect the average requirements to a greater
degree than environmental factors[179] and ancestry.[180] The poly-
morphismmost likely to inﬂuence the bioavailability of vitamins
are presented below.
5.2.1. Genetic Polymorphisms and Vitamin C Absorption
In literature, substantial variability in the serum ascorbic acid
response to a given amount of dietary vitamin is reported.[181]
Endogenous and exogenous factors may be responsible for
this variation, including the two sodium-dependent vitamin C
transport proteins, SVCT1 and SVCT2. They are speciﬁc for
the cotransport of sodium ions and ascorbic acid across cell
membranes and encoded by SLC23A1 and SLC23A2, respec-
tively. The transcriptional regulation of these genes controls the
distribution of SVCTs in tissues and is therefore responsible for
the maintenance of vitamin C levels in a wide range of cells, tis-
sues, and extracellular ﬂuids. Therefore, it can be assumed that
genetic alterations in SLC23A1 and SLC23A2 will have a sub-
stantial eﬀect on human vitamin C status. However, SLC23A1
knockout mice are still capable of absorbing ascorbic acid from
the diet,[182] but pharmacokinetics and viability of the oﬀspring
is severely aﬀected.[183] Although 1440 and 8165 variations of
SVCT1 and SVCT2, respectively, are listed in the SNP database,
not many of them have been veriﬁed in diﬀerent populations,
and most of them have neither been reported in the literature
nor functionally characterized (Table 2).[183] Whereas nearly all
SNPs in SLC23A2 are shared between African Americans and
Caucasians, a substantial number of SNPs in SLC23A1 are
population speciﬁc in either Caucasians or African Americans.
Apparently, SLC23A1 tolerates variations better than SLC23A2,
indicating a higher physiological importance for the latter. How-
ever, it could not be concluded, from a human study by Cahill
and El-Sohemy, that the SVCT1 and SVCT2 genotypes modify
the serum ascorbic acid response to dietary vitamin C.[184] On
the other hand, a collection of risk associations of several SNPs
in SLC23A1 and SLC23A2 by Shaghaghi et al.[183] indicated that
both vitamin C uptake and storage might be involved in the
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Table 2.Overview of polymorphism in genes involved in the processing of
vitamins and 𝛽-carotene by the GIT.
Protein Gene SNP (rs) Reference
Vitamin C
Sodium-dependent vitamin C
transporter 1
SLC23A1 rs11950646 [183,243]
rs33972313 [243]
rs10063949 [182]
rs4257763 [182]
rs6596473 [182]
Sodium-dependent vitamin C
transporter 2
SLC23A2 rs6053005 [183,243]
rs6133175 [183,243]
rs6116569 [183,243]
rs1279683 [244]
Glucose transporter type 2 SLC2A2 n.d. [183]
Glucose transporter type 3 SLC2A3 n.d. [183]
Vitamin B12
Galactoside 2-alpha-L-
fucosyltransferase 2
FUT2 rs602662 [188]
rs492602 [188]
rs602662 [188]
rs492602 [188]
Transcobalamin-1 TCN1 rs526934 [188]
Transcobalamin-2 TCN2 rs757874 [188]
Cubillin CUBN rs1801222 [188]
rs4748353 [188]
Serum
paraoxonase/arylesterase 1
PON1 rs3917577 [188]
Gastric intrinsic factor GIF rs121434322 [245]
rs35211634 [245]
Protein amnionless AMN rs386834170 [246]
rs386834169 [246]
rs386834175 [246]
rs386834165 [246]
Folate
Folate transporter 1, FOLT SLC19A1 rs1051266 [8]
rs2297291 [247]
rs12659 [247]
rs61510559 [248]
Proton-coupled folate
transporter
SLC46A1 rs2239907 [8,247]
rs5819844 [247]
Folate receptor alpha FOLR1 rs35179028 [8]
rs7928531 [247]
Cubilin CUBN rs780635 [188]
Folate Hydrolase 1 FOLH1 rs202676 [187]
Vitamin A
Retinol binding protein 4 RBP4 (Ile59Asn) (rs121918584) [196]
Gly75Asp (rs1218585) [196]
c.248 + 1G>A [195]
rs10882272 [195]
Transthyretin TTR rs1667255 [195]
Patatin-like phospholipase
domain-containing 3
PNPLA3 rs738409 [195]
(Continued)
Table 2. Continued.
Protein Gene SNP (rs) Reference
𝛽-carotene oxygenase 1 BCO1 rs6564851 [195]
BCO1 rs12926540 [195]
BCO1 rs7501331 [195]
BCO1 rs12934922 [195]
Hepatic lipase HL rs1800588 [195]
Lipoprotein lipase LPL S447X [195]
Scavenger receptor class B
member 1
SCARB1 SR-BI intron 5 [195]
rs61932577 [249]
Cluster determinant 36 CD36 rs1984112 [249]
CD36 rs1761667 [249]
CD36 rs7755 [249]
ATP-binding cassette
sub-family A member 1
ABCA1 rs10991408* [250]
ABCA1 rs2791952 * [250]
ABCA1 rs3887137 * [250]
ABCG5 rs2278357 [250]
Apolipoprotein B-100 APOB rs1042031 * [250]
rs35364714 * [250]
rs4643493 * [250]
𝛽-carotene oxygenase 1 BCO1 rs7196470 [250]
C-X-C Motif Chemokine
Ligand 8
CXCL8 rs1247620 [250]
rs1358594 [250]
rs6834586 [250]
Elongation Of Very Long Chain
Fatty Acids Protein 2
ELOVL2 rs3798709 [250]
rs911196 [250]
rs9468304 [250]
Intestine-speciﬁc homeobox ISX rs16994824 [250]
rs202313 [250]
rs5755368 [250]
Lipase C LIPC rs11857380 * [250]
rs12185072 * [250]
rs1869138 * [250]
Polycystin 1 Like 2 PKD1L2 rs8043708 [250]
Retinoid Isomerohydrolase RPE65 rs12139131 [250]
rs4926340 [250]
Superoxide Dismutase 2 SOD2 rs2501175 [250]
Transcription Factor 7 Like 2 TCF7L2 rs946199 * [250]
Vitamin D
Lipoprotein lipase LPL rs6586874 [201]
rs10096561 [201]
Intestine-speciﬁc homeobox ISX rs5754862 [201]
Ileal sodium/bile acid
cotransporter
SLC10A2 rs9558203 [201]
rs9555166 [201]
Vitamin D-binding protein GC rs6845026 [201]
Scavenger receptor class B
member 1
SCARB1 rs12580803 [201]
Pancreatic triacylglycerol
lipase
PNLIP rs2915775 [201]
rs3010494 [201]
7-dehydrocholesterol
reductase
DHCR7 rs11604724 [201]
(Continued)
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Table 2. Continued.
Protein Gene SNP (rs) Reference
ATP-binding cassette
sub-family A member 1
ABCA1 rs7043894 [201]
Multidrug resistance protein 1 ABCB1 rs2235023 [201]
rs10260862 [201]
Apolipoprotein B-100 APOB rs2854725 [201]
Microtubule-associated
protein RP/EB family
member 2
MAPRE2 rs1125425 [201]
BET1 homolog BET1 rs10464587 [201]
Arylamine N-acetyltransferase
2
NAT2 rs4921920 [201]
25-hydroxyvitamin D-1 alpha
hydroxylase
CYP27B1 rs28934604 [202]
1,25-dihydroxyvitamin D(3)
24-hydroxylase
CYP24A1 rs6068812 [202]
Vitamin E
Ileal sodium/bile acid
cotransporter
SLC10A2 rs1571513 [206]
rs9558203 [206]
rs16961116 [206]
rs12874168 [206]
rs2065550 [206]
Pancreatic triacylglycerol
lipase
PNLIP rs2915775 [206]
rs3010494 [206]
Sterol regulatory
element-binding protein 2
SREBF2 rs2839715 [206]
rs4822062 [206]
ATP-binding cassette
sub-family G member 1
ABCG1 rs468320 [206]
Niemann-Pick disease type C1 NPC1 rs62001882 [208]
rs141973731 [208]
rs139659653 [208]
rs114375162 [208]
n.d., not documented. The star (*) indicates SNP that were associated with the
variability of 𝛽-carotene bioavailability due to their involvement in the postpran-
dial metabolism of CMs [carry newly absorbed 𝛽-carotene from the intestine
to liver].
pathogenesis of diﬀerent diseases. Because these ﬁndings were
reported on an individual basis in only small studies, a validation
in larger cohorts is necessary.[183] Of note, fasting serum ascorbic
acid concentration is aﬀected by one common polymorphism in
SLC23A1[184] and the loss of SVCT1 results in reduced plasma
levels of vitamin C due to lack of renal reabsorption. Therefore,
the polymorphisms in SLC23A1 would increase the excretion
of ascorbic acid from the body and alter the dose-response
relationship between plasma vitamin C levels and dietary
vitamin C.[182]
5.2.2. Genetic Polymorphisms and Vitamin B12 and Folate
Absorption
The uptake of folate in the small, as well as in the large intestine,
is a speciﬁc pH-dependent, Na+ independent carrier-mediated
mechanism. Three speciﬁc carriers are known; the reduced fo-
late carrier (RFC, the product of SLC19A1), the proton-coupled
folate transporter (PCFT/HCP1, the product of SLC46A1) and
the GPI (glycosyl phosphatidyl-inositol)-anchored folate receptor
1.[8,185] However, only RFC and PCFT are known to be expressed
and functional in intestinal tract.[185] The RFC and PCFT are ex-
pressed at the apical membrane domain of the intestinal cells.
While RFC is predominantly expressed in the lower part of the
small intestine and in the large intestine, where pH is rather
neutral/slightly alkaline, PCFT is mainly expressed at acidic pH,
which is typical for the proximal part of the small intestine.[174,185]
The process of folate absorption in the intestine is regulated
by extracellular folate level. Thus, in folate deﬁciency the levels
of expression of RFC and PCFT are increased in the jejunum,
the ileum, and the colon.[185,186] Additionally, folate hydrolase 1
(FOLH1) an enzyme located on the intestinal brush bordermem-
brane is responsible for the cleavage of the polyglutamated tail
from naturally occurring food folate before it can be absorbed.
Cummings and colleagues showed, that carriers of the FOLH1
484 C variant could absorb naturally occurring food folate less
well than T carriers.[187]
Vitamin B12 exists in two coenzyme forms, the methyl-B12
and the 5′-deoxyadenosyl-B12. Blood and milk mainly contain
methyl-B12, whereas in most tissue the deoxyadenosil form ac-
counts for most of vitamin B12.[185] Dietary vitamin B12 can be
ingested either in its free or in a protein bound form.
As widely known, vitamin B12 and folate metabolism are
clearly linked and therefore genetic variants that modify vitamin
B12 availability may also inﬂuence folate status.[188] In a cross
sectional study to identify associations between common SNPs
in genes related to folate and vitamin B12 metabolism, or associ-
ated with B vitamin-related chronic diseases and biomarkers of
nutrient status in a population exposed to folic acid fortiﬁcation,
Zinck and co-authors found 14 SNPs in 11 genes associated with
red blood cell folate and serum vitamin B12 status. Only 6 of the
14 SNPs are related to protein location and function in the stom-
ach or intestine (see Table 2). As already described elsewhere,
common variants in exon 2 of fucosyltransferase 2 (FUT2) were
also identiﬁed in this study and were associated with higher
vitamin B12 status. The authors hypothesize that these variants
reduce the risk for Helicobacter pylori infection mostly related to
gastritis induced vitamin B12 malabsorption. A second hypoth-
esis proposed that these FUT2 variants increase the secretion of
a gastric intrinsic factor, a fucosylated glycoprotein required for
the absorption of vitamin B12. In contrast to the improvement
of vitamin B12 status by the above mentioned variations, two
SNPs on the vitamin B12 binding proteins transcobalamin I
(rs526934, intron 8) and II (rs757874, intron4) are associated
with lower vitamin B12 status.[188] Transcobalamin I is produced
by salivary glands in the mouth and the gastric mucosal cells in
the stomach, and protects vitamin B12 from acid degradation
during the transport in the stomach. Transcobalamin II binds
vitamin B12 after uptake by the enterocytes of the terminal
ileum.[189]
The vitamin B12-intrinsic factor complex receptor in the distal
ileum is called cubilin (CUBN). The CUBN rs1801222 poly-
morphism results in a reduced functionality of CUBN, thereby
lowering vitamin B12 absorption. A genetic variant that there-
fore may modify vitamin B12 availability and status indirectly
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inﬂuences the folate status. Because the vitamin B12 dependent
MTR enzyme is required to convert 5-methyltetrahydrofolate,
this folate form is then taken up into cells from circulation, and
converted to tetrahydrofolate, which no longer diﬀuses out of the
cell.[188]
Of note, there are also relatively rare inherited defects
in intestinal absorption of vitamin B12 (e.g., due to muta-
tions in genes such as cobalamin binding intrinsic factor
(CBLIF), amnion associated transmembrane protein (AMN), and
CUBN).[8]
5.2.3. Genetic Polymorphisms and Vitamin A Absorption
In general, fat-soluble vitamin absorption follows the same
mechanisms as fat absorption.[190] The absorption of vitamin A
depends on its dietary form. From the over 600 carotenoids iso-
lated from natural sources, only 60 have been detected in the hu-
man diet and 20 of these in human blood and tissues, with the
most prominent being 𝛽-carotene, 𝛼-carotene, lycopene, lutein,
and 𝛽-cryptoxanthin.[191] Retinol, retinal, retinoic acid, and retinyl
esters are the diﬀerent forms of retinoids, detected in animal
sources.
Vitamin A (as retinol and retinyl ester) uptake by intestinal
mucosa is preferentially localized in the proximal intestine.
Interestingly, vitamin E presence signiﬁcantly improves vi-
tamin A uptake, when at medium and high concentrations
(up to 40%).[192]
Information is limited regarding the physical forms of retinyl
esters and carotenoids in the intestinal lumen, however it is clear
from human and animal studies, that the co-ingestion of dietary
fat and vitamin E enhances the intestinal absorption of dietary
vitamin A and carotenoids. Lipids also facilitate the conversion
of pro-vitamin A to vitamin A. Intestinal carotenoid and retinol
absorption is preferentially localized in the proximal intestine
and beside passive diﬀusion, also facilitated by speciﬁc active
transporters at concentrations below saturation. Pro-vitamin A
carotenoids such as 𝛼- or 𝛽-carotene are partly converted to retinol
by oxygenase and reductase enzymes and the produced retinol
is then available for uptake by intestinal mucosa.[193,194] Informa-
tion on plant derived carotenoids is therefore only focused on this
converted part.
Data on genetic variations in vitamin A bioavailability is scarce
and most existing data focuses on 𝛽-carotene.[5] Both absorp-
tion eﬃciency and vitamin A tissue uptake vary by genetic vari-
ations in blood binding proteins such as retinol binding protein
4 (RBP4) aﬀecting blood retinol concentrations.[195] A GWAS has
conﬁrmed that SNPs in the two genes encoding the proteins that
transport retinol in the blood, i.e., RBP4 and transthyretin (TTR),
which cause amino acid substitutions at position 84 of the TTR
molecule (Ser84 and Asn84), can signiﬁcantly aﬀect blood retinol
concentrations.[196] Additionally, blood levels of retinol were asso-
ciated in some cases with a SNP in phospholipase domain con-
taining 3.
Interestingly, genetic variations in proteins/enzymes located
in tissues can also aﬀect fasting blood retinol concentration. For
example, an association between SNPs in beta-carotene oxyge-
nase 1 (BCO1) and blood retinol was found,[197] suggesting that
carotenoids signiﬁcantly participate in blood retinol concentra-
tions. As work in this area is limited, more research is required to
identify additional SNPs relevant to vitaminA status and bioavail-
ability.
5.2.4. Genetic Polymorphisms and Vitamin D Absorption
Vitamin D exists in two major forms, vitamin D2 (ergocalciferol)
of plant and fungal origin and vitamin D3 (cholecalciferol) de-
rived from animal food and endogenous synthetization in the
skin. The intestinal absorption of vitamin D is similar to that
of vitamin A.[8] There are three known transporters: SRBI (scav-
enge receptor class B type 1), CD 36 (cluster determinant 36) and
NPC1L1 (Neimann–Pick C1-like 1), but the diﬀerences between
absorption rate in the duodenum and the jejunum indicates the
presence of another transporter, particularly expressed in the je-
junum. Several other factors inﬂuence the bioavailability of vita-
minD like nutrient status in the host, form, foodmatrix, amount,
and composition of ingested food, amount of lipids, type of fatty
acids, dietary ﬁbers, activities of digestive enzymes, eﬃciency of
transport across enterocytes, interactions with micronutrients,
age of host, obesity, genetic variations, and therefore, contribute
to the interindividual variability of vitamin D absorption.[198,199]
Beside the absorption of vitamin D, also the endogenous synthe-
sis varies, depending on the type and nature of skin pigments and
the age of the host, as the vitamin D production in the skin, as
well as the conversion of 25OHD into 1,25(OH)2D (active form)
in the kidneys, decreases with age.[190,200]
Current understanding regarding genetic polymorphisms
related to the absorption and metabolism of vitamin D2 and
D3 is limited. Nevertheless, high variability has been observed
among individuals in response to vitamin D supplementation.
Desmarchelier and colleagues[201] assessed the relation between
genetic polymorphisms and variability in vitamin D3 bioavail-
ability. In 39 healthy adult men, a 34-fold diﬀerence in area under
the curve (AUC) was observed in postprandial vitamin D3 re-
sponse. 17 SNPs (rs6586874, rs10096561, rs5754862, rs9558203,
rs6845026, rs12580803, rs2915775, rs11604724, rs7043894,
rs2235023, rs10260862, rs3010494, rs2854725, rs1125425,
rs10464587, rs4921920, and rs9555166) located in or near 13
genes, which encode for several active transporter mechanisms
(LPL, ISX, SLC10A2, GC, SCARB1, PNLIP, DHCR7, ABCA1,
ABCB1, APOB, MAPRE2, BET1, and NAT2; see Table 2), which
further supports the notion that, at nutritional doses, uptake of
vitamin D is at least in part an active, rather than the previously
thought passive process. These 17 SNPs explained 63.5% of the
observed interindividual variance. In regards to metabolism,
the enzymes 1a-hydroxylase and 24-hydroxylase have been
identiﬁed to contribute to interindividual variability. Encoded for
by CYP27B1 and CYP24A1, respectively, these enzymes are of
critical importance in governing calcitriol (synthetic version of vi-
tamin D3 used in clinical applications) concentration. These two
enzymes work jointly to regulate the concentration of calcitriol
at the tissue level. Genetic polymorphisms in both CYP27B1
and CYP24A1 have been identiﬁed. SNP’s rs28934604 and
rs6068812, respectively, have both been shown to signiﬁcantly
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reduce calcidiol to calcitriol conversion rate in 1a -hydroxylase
and 24-hydroxylase.[202–204]
5.2.5. Genetic Polymorphisms and Vitamin E Absorption
Vitamin E is the term for a group of four diﬀerent tocopherols
and four diﬀerent tocotrienols. They are all fat-soluble antioxi-
dants and 𝛼-tocopherol is the best-known and studied compo-
nent of vitamin E. Vitamin E is essentially absorbed in the distal
part of the intestine with a signiﬁcant uptake in the jejunum.[205]
It is absorbed together with dietary fats incorporated into mixed
micelles mainly by passive diﬀusion. However, newer ﬁndings
show that several proteins, like NPC1L1, sterol regulatory ele-
ment binding protein 2 (SREBP2) or scavenger receptor class B
type I (SR-B1), as well as CD36 molecule and apical sodium-bile
acid transporter, facilitate the uptake of vitamin E. Also inside
the enterocyte, diﬀerent candidates (e.g., L-FABP or tocopherol-
associated protein) for the intracellular transport have been
described.[205] The bioavailability varies greatly from 10% to 81%
due to inﬂuencing factors like composition of food matrix, pres-
ence and type of fat, pathologies, or genetic factors of the host.[205]
Studies in mice and Caco-2 cells showed an interaction between
vitamin D and vitamin E, reducing the vitamin E uptake by 35%
in cases of a co-intake of pharmacological doses of vitaminD. The
reason could be that these two vitamins share common transport
proteins like NPC1-L1 and SR-BI.
Current understanding regarding genetic polymorphisms re-
lated to the absorption and metabolism of vitamin E is limited.
However, genetic polymorphisms in genes coding for vitamin E
and lipid intestinal metabolism have been associated with amod-
ulation of vitamin E bioavailability in humans, due to the shared
intestinal transport pathway between dietary lipids and vitamin
E (incorporation into mixed micelles).[206]
Borel and colleagues[207] assessed the relation between genetic
polymorphisms and variability in 𝛼-tocopherol bioavailability in
an 𝛼-tocopherol supplementation trial. In 40 healthy adult men,
an 81% postprandial variation in 𝛼-tocopherol was observed. A
total of 28 SNPs in or near 11 candidate genes were associ-
ated with 82% of interindividual variability of 𝛼-tocopherol. Four
of these genes (SLC10A2, PNLIP, SREBF2, and ABCG1), with
their related SNPs (SLC10A2 rs1571513, rs9558203, rs16961116,
rs12874168, rs2065550; PNLIP rs2915775, rs3010494; SREBF2
rs2839715, rs4822062; ABCG1 rs468320; see Table 2) were
identiﬁed as being speciﬁcally associated with 𝛼-tocopherol
response.[206,207]
The membrane protein NPC1L1 plays a crucial role in
the absorption and movement of lipophilic compounds like
cholesterol and vitamin E. Yamanashi and colleagues found
four SNPs (Ala395Val (rs62001882), Gly402Ser (rs141973731),
Arg417Trp (rs139659653), and Gly434Arg (rs114375162)) dimin-
ishing transport activity by 21% to 63% compared to the wild
type, concluding, that this will inﬂuence bioavailability of vitamin
E.[208]
Apolipoprotein A5 (APOA5), which is encoded by APOA5,
plays an important role in regulating plasma triglyceride levels.
Polymorphism in APOA5 is signiﬁcantly associated with TAG
concentration in the plasma. The speciﬁc SNP rs662799 of this
gene, has been associated with higher vitamin E plasma concen-
tration, suggesting that vitamin E transportation may be regu-
lated by APOA5 in vivo.[202,209]
6. Minerals
6.1. Overview of Mineral Processing by the GIT
Minerals and electrolytes intestinal absorption and secretion pro-
cesses are governed by active and passive mechanisms. Both
mechanism may occur simultaneously but also may occur as as-
sociated transport with other substances.[210] Mineral intestinal
absorption depends on the small or large intestine and, even
more, between the three small intestinal segments (duodenum,
jejunum, ileum). In addition, some minerals are present in non-
absorbable forms, such as the insoluble ferric iron (Fe3+), which
needs to be reduced to absorbable ferrous iron (Fe+2) by duode-
nal brush border cytochrome B reductase 1 (DCYTB; CYBRD1),
as well as luminal Cu2+ to Cu+. Dietary ascorbic acid can also
mediate Fe3+ reduction.[8]
6.1.1. Intestinal Absorption of Minerals
Three general intestinal absorptionmechanisms have been iden-
tiﬁed for minerals: 1) non-transporter mediated passive diﬀu-
sion driven by a concentration gradient (paracellular pathway),
2) transport mediated by a membrane transporter (active trans-
port), and 3) mineral co-transport with other substances such as
sugar or amino acids.
The paracellular pathway consists of substances diﬀusion
through the enterocyte tight junctions driven by the concentra-
tion gradient, but is also governed by epithelial ionic electrical
resistant selectivity. This mechanism does not shows directional
discrimination.[211] Although no protein channels or transporters
are involved in paracellular transport, the lateral intercellular
space can inﬂuence the paracellular electrical resistance, as oc-
curs with the claudin proteins during Ca2+ absorption. Besides, a
“solvent drag eﬀect,” linked transport with oxalates of somemin-
erals may occur too.[8]
Transcellular mineral transport may be mediated by a mem-
brane transporter protein. Ca is absorbed by the saturable
transcellular transporters TRPV6 and TRPV5 at low luminal
concentrations, whereas active transport by the apical L-type
channel Cav1.3 occurs at high concentrations. The active trans-
porters TRPM7 and TRPM6 are responsible forMg2+ absorption.
Divalent metal ions are mainly transported by the divalent metal
transporter 1 (DMT1, also known as DCT1 or Nramp2), and by
other transporters (SLC39A4, (Zip4); SLC31A1 (CTR1); SLC39A8
(Zip8), and Zip14A/Zip14B). Several proteins belonging to the
SLC26 “sulphate permease” transporter family are responsible
for SO4− and oxalate anion intake, in a Na+ independent manner
(SLC26A1 (SAT1); SLC26A2 (DTDST), and SLC26A3 (DRA)), to-
gether with oxalate intestinal intake driven by SLC26A7 (SUT2).
Others active transport mediated by SLC26 proteins may occur,
such as anion electroneutral exchangers (DRA/CLD exchanger;
SLC26A3) or the ion exchangers PAT1 (SLC26A6a), capable to
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Figure 3. Overview of polymorphisms involved in mineral absorption by the GI tract.
exchange Cl−/oxalates, SO4−/oxalates, SO4−/Cl−, and Cl−/OH−.
Electrogenic Na+ absorption happens mediated by the epithelial
sodium channels (ENaC), however, a not yet completely deﬁned
Na+/HCO3− cotransporter (NBC) may act too.[8]
A mineral–mineral or mineral–nutrient intestinal cotransport
may also occur. SLC9 Na+/H+ exchangers (as SLC9A3) drive
electroneutral NaCl absorption, whereas a Na+/H+ antiporter
(NHE2, NHE3, and NHE8 isoforms) has also been identiﬁed.[8]
Phosphate intake may occur through an apical Na+-phosphate
cotransporter driven by NaPi-IIb (SLC34A4).[212]
In addition, other mineral transport may occur associated to
other nutrients, such as SGLT1, which allows a Na+-glucose co-
transport (in a 2:1 ratio) mediated by a Na+ electrochemical gra-
dient, or the diverse SLC6 and SLC1 transporters, which allow
the transport of some amino acids in a Na+ manner.[8]
6.1.2. Intestinal Secretion of Minerals and Mineral Exit
When mineral secretion or eﬄux is considered, diﬀerent mech-
anisms have been identiﬁed for the diﬀerent minerals. Ca baso-
lateral enterocyte exit occurs by twomechanisms enhanced by vi-
tamin D3: mainly via Ca2+-ATPase PMCA1b (80% contribution)
and through the Na+/Ca2+ exchanger NCX1 (SLC8A1).
PAT1 (SLC26A6) is responsible for oxalate cellular eﬄux and
intestinal secretion.
After Zn apical absorption across Zip4 transporter, vesicular
transport driven by the Znt protein occurs, allowing Zip5 baso-
lateral transport, whereasmetallothionein (MT) acts as a intracel-
lular Zn binding protein.
Fe basolateral exit, probably shared for Cr andMg exit, is driven
by the SLC40A1 (FPN1) coupled to an Fe2+ oxidation process
(iron oxidase hephaestin, HEPH), allowing binding oxidized iron
to transferrin.
Once Cu+ is absorbed, it is transferred to the basolateral mem-
brane by a number of intracellular chaperones, such as ATOX1,
which delivers Cu+ to ATP7A P-type ATPase present in the trans-
Golgi network (for cuproenzyme synthesis) or at the basolateral
membrane.[8]
Among the variables presented in the last paragraph of the In-
troduction, a search of the literature has identiﬁed convincing ev-
idence for the interindividual variability of the intestinal absorp-
tion of minerals by the GIT for the following variables: genetic
polymorphisms.
6.2. Interindividual Variability in Intestinal Absorption of Minerals
6.2.1. Genetic Polymorphisms Aﬀecting the Intestinal Processing
of Minerals
Diverse studies have been conducted to elucidate the existence
and inﬂuence of polymorphism and/or mutations in the mineral
absorption and metabolism (Figure 3). For example, congenital
chloride diarrhea (CLD) is an autosomal recessive disorder of
intestinal electrolyte absorption, characterized by persistent
secretory diarrhea, causing dehydration and hypoelectrolytemia.
CLD is caused by mutations in the solute carrier family 26,
member 3 gene (SLC26A3, CLD or DRA), which encodes a
Na+-independent Cl−/HCO3− (or OH−) exchanger. A wide
variety of diﬀerent mutations in SLC26A3 have been associated
with CLD with no apparent evidence of phenotype–genotype
correlation. The clinical course of CLD, however, is variable and
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may rather depend on environmental factors and compensatory
mechanisms than mutations.[213]
Various chronic diseases have been associated tomineral cellu-
lar transporters polymorphisms. However, most of the results do
not show a clear link between the disorders and a lack or dysfunc-
tion of the intestinal absorption.Most studies focusing on the im-
pact of these polymorphisms in other organs such as kidney or
liver.[214,215] Thus, apart from iron for which signiﬁcant evidences
are available (see next section),[215] only limited information exists
on the impact of polymorphisms on the intestinal absorption of
minerals. This evidence is summarized below.
Intestinal absorption of zinc happens through an active trans-
port mediated by Zip4 and DMT1.[8] Besides, numerous pro-
teins having been shown to be involved in zinc metabolism and
homeostasis through the inﬂux, chelating, sequestrating, coor-
dinating, releasing, and eﬄux of zinc, with metallothioneins,
Zrt- and Irt-like proteins (ZIP), and Zn transporters (ZnT) be-
ing among them.[216] Metallothioneins are cysteine-rich proteins
allowing the binding of biologically essential metals and man-
aging metal homeostatic regulation, as well as absorbing heavy
metals. In the case of zinc, the metallotheonin is an intracellu-
lar binding protein, acting as a storing and reservoir protein. Re-
search was conducted in a Turkish population, with the aim of
identifying the correlation between a polymorphism in the core
promoter region-5 A/G of metallothionein 2A (MT2A) and Cd,
Pb, Zn, and Cu levels in blood samples. The genotype AA (typi-
cal homozygote) was found at 86.6% frequency, the heterozygote
AG at 12.8% frequency and the atypical homozygote GG at 0.6%
frequency. The atypical heterozygote correlated signiﬁcantly with
Cd, Pb, and Zn levels in blood, but not with Cu levels. The au-
thors suggested a genetic predisposition in the accumulation of
the heavy metals Pb and Cd caused by diﬀerent intestinal ab-
sorptionmediated by 2A (MT2A) polymorphism. In addition, the
GG population was characterized by lower Zn levels in blood but
higher Cd and Pb levels.[217] The lower Zn levels in the GG pop-
ulation can be explained by the fact that competitive intestinal
transport occurs when diﬀerent metal ions share the same pro-
tein transporter. However, more research is necessary to further
understand these relationships.
DMT1 transporter is a protein especially involved in duode-
nal Fe transport, but also in Zn, Mn, Co, Cd, Cu, Ni, and Pb
uptake.[217] Low levels of Fe cause higher DMT1 intestinal ex-
pression, whereas overexpression of this transporter increases
the intestinal Fe absorption as well as Pb and Cd absorption
too. Four major mammalian DMT1 isoforms have been discover,
named A/+IRE, 1A/–IRE, 2/+IRE, and 2/-IRE. The +IRE forms
are mainly located in the apical side of the epithelial cells, espe-
cially in the duodenum. A study conducted by Kayaalti et al.[217]
investigated the inﬂuence ofDMT1 IVS4+44 C/A polymorphism
(located in the intron 4 of DMT1) in Fe serum levels, as well as
Pb and Cd blood levels. The genotype frequencies were 49.8%
for the CC typical homozygotes, 38.3% for the heterozygote, and
11.9% for the AA atypical homozygote. The authors suggested
that DMT1 IVS4+44 C/A polymorphism is associated with in-
terindividual variations in blood Fe and Pb levels, but not Cd,
since this protein transporter is mainly responsible for intestinal
uptake of dietary divalent metals. The CC genotype group had
higher Fe and Pb blood levels, indicating that the absence of the
A allele leads to higher iron and Pb intestinal absorption. Thus,
carriers of the CC genotype may be more susceptible to metal
toxicity as compared to those with AC and AA genotypes.[217]
Abrams et al.[218] carried out a study of calcium absorption and
vitaminD receptor (VDR) Fok1 polymorphism. A signiﬁcant rela-
tionship was found between this polymorphism and calcium ab-
sorption, whereas no relation was found for other VDR polymor-
phisms such as ApaI, BsmI, and Taq1 genotypes. The same re-
sults were obtained in estrogen receptor genotypes for XbaI and
PvuII, as well as for calcitonin receptor genotypes. The homozy-
gotes FF, to VDR Fok1 polymorphism, showed higher calcium
fractional absorption at the end of the study, with FF being lower
compared to Ff and ﬀ genotypes. These results suggest that the F
allele, and therefore the FF genotype, allows higher calcium ab-
sorption. In agreement with this result, calcium levels at the be-
ginning of the study was signiﬁcantly higher in the FF genotype
group (315 ± 19 mg d–1) in comparison with Ff (258 ± 17 mg d–1)
and ﬀ (224 ± 27 mg d–1) genotypes.[218]
6.2.2. Genetic Polymorphisms Aﬀecting the Intestinal Processing
of Iron
Iron is an essential mineral with a dietary intake estimated as
20–30 mg d–1, however, only 1.5 mg is absorbed by adult males.
Adult females require additional 1.5–2 mg d–1ay to compen-
sate for losses through menstrual bleeding and fetal require-
ments during pregnancy. The human body contains 3–5 g of iron
stores, mostly present in hemoglobin ormyoglobin.[8] Signiﬁcant
sources of variation in the indices of iron status include age, sex,
body–mass index, and genetic factors.[219]
No iron excretion pathways exist in humans, excepting losses
in epithelial cells and ﬂuids such as blood, tears, and sweat.[220]
Therefore, iron absorption is the primary determinant of iron
balance, where a homeostatic mechanism avoids the iron over-
load. Iron bioavailability is conditioned by the digestion process,
modulated in turn by the presence of dietary substances with
iron-binding (e.g., phytate, tannins) or reducing capacities (e.g.,
ascorbic acid). In addition, since divalent metal ions share di-
verse intestinal absorption transporters, the intestinal transport
of iron may compete with other divalent cations uptake.[221]
Since non-heme iron is absorbed by DMT1, the insoluble Fe+3
reduction to Fe+2 must be mediated by the duodenal brush bor-
der cytochrome b reductase 1 (DCYTB; CYRD1) as well as by di-
etary ascorbic acid.[220] Conversely, heme iron transport occurs
via the low aﬃnity heme transporter HCP1 (SLC46A1). Both iron
transporters are overexpressed in response to hypoxia[8] whereas
DMT1 increases to anemia.[220]
The absorbed Fe+2 may either be bound to ferritin or be
exported into the bloodstream.[220] Fe2+ is transported into
vesicles containing either ferroportin (FPN1) or hephaestin
(HEPH), crossing the enterocyte cytoplasm to the basolateral
membrane.[222] The exit of Fe across the enterocyte basolateral
membrane occurs through the transporter FPN1, coupled to the
ferroxidase activity of the basolateral HEPH, allowing the iron
binding to transferrin protein in the interstitial ﬂuid and plasma
for body distribution.[222]
The liver hepcidin antimicrobial peptide (HAMP) is se-
creted from the liver in response to the body iron stores and
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inﬂammation (via IL-6).[8] HAMP directly binds to FPN1 caus-
ing to be internalized and degraded, thereby blocking cellular
iron export. Adequate or high iron stores in the liver result
in increasing of HAMP secretion and a decreasing of FPN1
mRNA expression, lowering FPN1 levels. The result of this
repositioning of the FPN1 from the basolateral membrane is to
reduce iron eﬄux from across the basolateral membrane of the
duodenocyte, and thereby a decrease in iron absorption.[221,222]
Hereditary hemochromatosis (HH) is a heterogeneous disor-
der of iron metabolism related to theHFE gene.[223] HFE protein
is found in duodenal crypt cells associated with b-2 microglobin
and transferrin receptors. HFE mutations prevent Fe from being
taken into the crypt cells, leading to Fe deﬁciency in the duodenal
crypt cells. This, in turn, increases DMT1 expression and activ-
ity, resulting in abnormally elevated iron absorption. Progressive
accumulation of iron may provoke serious clinical consequences
including diabetes, heart disease, arthritis, and cirrhosis.[221,222]
Most people are homozygous for the C282Y mutation of
HFE, with the minority being heterozygotes (C282Y, H63D),
but the clinical penetrance is low. Since hepcidin expression is
inappropriately low in hemochromatosis disorder, it has been
suggested that the HFE protein is required for normal reg-
ulation of hepcidin synthesis. However, clinical penetrance is
low in C282Y homozygotes, so that the phenotype is not re-
lated to HFE alone.[221,222] The most common form of the dis-
ease is classic or type 1 HH, mainly caused by a bi-allelic mis-
sense pCys282Tyr (c.845G N A) mutation in HFE. The role
of rs10421768, rs235756, rs2230267, and rs1439816 polymor-
phisms, respectively inHAMP, BMP2, FTL, and SLC40A1 (these
genes are involved in iron metabolism pathways, principally in
the hepcidin expression cascade) in hereditary hemochromatosis
expressivity, suggests a hypotheticalmultifactorialmodel, charac-
terized by a principal gene (HFE inHH type 1) andminor genetic
and environmental factors that still must be fully elucidated.[223]
Hepcidin expression is also low in juvenile hemochromatosis,
a rare but severe iron loading disorder associated with mutations
ofHFE2 (hemojuvelin). As several other mutations are responsi-
ble for hereditary hemochromatosis, this condition is now sepa-
rated into four categories: 1) Type 1 (HFE mutations), 2) Type 2
HFE2 (hemojuvelin) mutation, 3) Type 3 (TfR2 mutation), Type
4 (ferroportin mutation).[221]
The ferroportin (FPN1) Q248H polymorphism, which typi-
cally occurs in sub-Saharan and African Natives and African
Americans, has been associated with higher ferritin serum lev-
els. In a study by Rivers et al.,[224] 10.4% of cases with high serum
ferritin levels in an American population were heterozygotes for
Q248H, compared with 6.7% of the heterozygotes who had nor-
mal ferritin level. In addition, serum ferritin levels were asso-
ciate withCYBRD1 rs884409,[225] a polymorphism localized to the
proximal region of the CYBRD1 promoter. In this study, partici-
pants with one or two copies of the minor allele of rs884409 had
lower levels of serum ferritins. This polymorphism decreases the
basal activity of the promoter by 30%. Decreased expression of
CYBRD1 in turn results in a lower reduction of Fe, an essential
step in intestinal iron intake. Of note, a reduced intestinal iron
intake can be a protective mechanism against iron overload in
C282Y homozygotic populations.
Mutations in FPN1 (SLC40A1) lead to an autosomal dominant
form of hemochromatosis (type 4), also known as ferroportin
disease.[226] Also, raremutations in DMT1 (SLC11A2) are respon-
sible for an absorptive defect leading to hypochromic microcytic
anemia. Secondary interference with DMT1 function can occur
in intestinal disorders like coeliac disease, which damages the
duodenal villus structure rendering patients unable to absorb
iron. Therefore, patients who are Fe-deﬁcient and nonresponsive
to iron supplementation need to be investigated for coeliac
disease.
Much less is known about the genetic basis of non-diet re-
lated iron deﬁciency. A polymorphism in the transferrin protein
(G277S) has been associated with iron deﬁciency, but no eﬀect of
the SNP on the iron-binding capacity of transferrin was observed
from in vitro studies. A human iron absorption study also failed
to show a signiﬁcant diﬀerence between heterozygote and wild-
type individuals, although there was a diﬀerence in the slope of
the curve describing the relationship between body iron stores
(serum ferritin) and percentage iron absorption.[221]
7. Discussion
From a research point of view, the realization that human
metabolism has signiﬁcant interindividual variability fundamen-
tally leads to a personalization of human physiology. The GutSelf
review therefore ﬁlls an important gap by providing, for the ﬁrst
time, a global overview of the inter-individual variability in the
processing of nutrients by the human GIT.
The ﬁrst lesson learned from our analysis of the literature
was that interindividual variability is yet to be investigated as a
key “primary endpoint” with nutritional research. This said, the
GutSelf review highlights multiple “regions” of the multidimen-
sional space describing the interaction of foods with the human
GIT. The bioavailability of amino acids derived from dietary pro-
teins varies depending on the quality of the chewing process, the
amounts and proteolytic activity of pepsin, pancreatic and intesti-
nal proteases, modulating protein hydrolysis, and the polymor-
phisms in amino acid transporters, modulating amino acid ab-
sorption. Variability in fat processing by the GIT is characterized
by signiﬁcant diﬀerences in the ability of humans to sense fatty
acids, in particular due to polymorphisms in CD36, by variability
in the activity of gastric lipase, and by variability in the absorption
and secretion into the circulation of fatty acids, cholesterols, or
phytosterols, via a range of, as to yet, uncharacterized biochem-
ical and genetic factors, including transporters involved in the
intestinal processing of CMs. With regard to carbohydrates, the
importance of the chewing process, the role of the copy num-
ber of the amylase genes, the presence of an active lactase, the
functionality of glucose transporters, as well as the diversity of
the microbiota are clear elements mediating interindividual vari-
ability in the digestion and absorption of this group of nutrients.
Variability in the bioavailability of vitamins is mostly mediated
by polymorphism in intestinal transporters such SVCT vitamin
C transporters, FUT2 and CBN for vitamin B12, CYP27B1 and
CYP24A1 for vitamin D, APOA5 for vitamin E. Finally, although
scarce, studies on the genetic variability of the gastrointestinal
absorption of minerals seem to indicate that the bioavailability
of minerals is potentially inﬂuenced by polymorphisms in recep-
tors, the most obvious polymorphism being reported in genes,
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such asHFE, FPN1, CYBRD1, FPN1, or DMT1, involved in iron
transport.
That the microbiota has been most obviously reported to con-
tribute to the interindividual variability in the GIT processing of
carbohydrate is symptomatic of the fact that carbohydrates are the
major source of energy and, consequently, growth, for intestinal
microbes.[166] Although variability in the gut microbiota is largely
recognized as an important factor in personalized nutrition,[227]
only few examples directly associate a diﬀerential processing of
nutrients by the GIT with variation in the gut microbiota, among
them the metabolism of ﬂavonoids[228] and the production of
trimethylamine-N-oxide.[229] Finally, the metabolic interplay be-
tween nutrients, the gut microbiota, and the host is complex and
multidirectional, each component feeding back molecular or cel-
lular signals to the others following their own stimulation.[227,230]
In this context, the current study designs do not allow to ﬁlter out
how variability in the gut microbiota modulates the metabolism
of nutrients by the GIT.
Despite numerous indications of interindividual variability in
the processing of food by the human GIT, the knowledge on this
topic remains fragmented to a large extend because of a lack of
speciﬁc focus of researchers on these issues. Also, a quantitative
understanding of the clinical relevance of most of the interindi-
vidual responses to food ingestion remains unknown. Fostering
personalized nutrition will request a conceptual analysis of the
identiﬁed variables triggering interindividual variability in the re-
sponse of human to dietary intake. To more precisely identify
these variables, human nutritional trials will need to systemat-
ically report data on individual subjects. In addition, as interindi-
vidual variability of a biological variable can only be claimed if
the precision of the analytical methods measuring the variable is
better than the biological variability, the performance of the ana-
lytical tools should be documented. Implementing these recom-
mendations should, at term, promote translation in nutritional
sciences and realize the statement made in the introduction of
this review: “Tell me what you digest and absorb, and I will tell
you what you are.”
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